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ABSTRACT 
________________________________________________________________________ 
Nucleic acid binding proteins are key regulators in developmental processes and 
controlling the onset of diseases. Human SOX9 is a group E member of the SOX 
transcription family of proteins characterized by a conserved amino acid region first 
identified as the high mobility group (HMG) with high affinity for DNA. In parallel, a 38 
amino acid region preceding the HMG domain described as the dimerization domain 
supports the formation of cooperative dimers on promoters with inverted sites, by binding 
to the HMG domain. Cooperative binding occurs when the binding at a first site increases 
the rate at which binding occurs at a second site between identical or non-identical 
proteins. Using mutagenesis and electrophoretic mobility shift assays (EMSA) the trans-
dimerization model of dimeric SOX9 binding to DNA was studied. The molecular 
model of the SOX9 dimeric complex is characterized as a dimer by way of the 
amphipathic helix of the dimerization domain of one SOX9 protein docks on the HMG 
domain of an identical SOX9 protein in the DNA-bound state. Cooperative binding of 
one protein to the consensus-binding site may facilitate binding to the non-consensus 
site. This model provides insight to the characterized mutations associated with 
Campomelic dysplasia, an embryonic malformation of the skeletal and reproductive 
system. 
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CHAPTER I 
LITERATURE REVIEW 
________________________________________________________________________ 
1.1 The High Mobility Group (HMG) Family of Proteins 
High mobility group (HMG) proteins originated from their high electrophoretic 
mobility on polyacrylamide gels (Bianchi and Agresti, 2005). They are the second most 
abundant chromatin binding proteins after histones (Bianchi and Agresti, 2005). HMG 
proteins contribute to the fine-tuning of transcription (Bianchi and Agresti, 2005). This 
group exerts inclusive genomic functions via the establishment of inactive and active 
chromatin domains and ultimately regulating genome accessibility (Bianchi and Agresti, 
2005). The HMG domain consists of three alpha helices separated by loops that have a 
high affinity for bent, distorted, or linear DNA (Thomas, 2001). HMG proteins can be 
divided into three derived families based on their function (Figure 1) (i) the HMG-I(Y) 
or AT-hook family, (ii) the HMG-14/17 or nucleosome binding family, and (iii) the 
HMG1/2 or HMG-box family (Bianchi and Agresti, 2005). The HMG-box family can 
further be sub-characterized by the protein either binding to bent DNA described as the 
canonical HMG domain, while a small subset retain the propensity to bind to a specific 
sequence and induce a bend in the DNA, defined as the non-canonical HMG domain.  
1.2 The Sox Family of Proteins: A Non-Canonical DNA-Binding Protein Family 
The Sex-Determining Region Y (SRY) of the Y chromosome and the Sry-related 
HMG box (SOX) are transcription factor regulators that retain dynamic roles in 
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hook	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HMG	  Domain	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  A	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  B1	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Sox8	  
Sox9	  
Sox10	  
Group	  F	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HMG-­‐14/17	  or	  
Nucleosome	  
Binding	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Figure 1: Schematic representation of the High Mobility Group (HMG) family. Sox9 is a 
transcription factor that is part of the Group E family of Sox proteins that binds DNA via a non-
canonical HMG domain. (Recreated from Shokofeh Shahangian)    
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vertebrate developmental processes. SOX; expressed in Homo sapiens, or Sox; expressed 
in lower organisms, are a family of DNA-binding proteins. Sox proteins bind to 
ATTGTT sequence motifs via their HMG domain (Kamachi and Kondoh, 2013). It is the 
binding of the HMG domain to the minor groove of DNA that elicits bending in the DNA 
towards its major groove (Kamachi and Kondoh, 2013). The HMG domain in mice, 
adapted from Kamachi and Kondoh (2013), can be illustrated as a phylogenic tree 
(Figure 2A) defining classifications of SOX proteins from groups A to H as a result of 
genome duplication (Kamachi and Kondoh, 2013). Such groups differ in the amino acid 
sequence of the HMG domain (Figure 2B), however within a single group conservation 
of amino acid sequence homology and protein domain organization is maintained by 
sharing greater than 80% amino acid identity (Sarkar and Hochedlinger, 2013; Wegner, 
1999). Structures outside of the HMG box diverge between mammalian species while the 
HMG in itself remains highly conserved (Kamachi and Kondoh, 2013). Redundancy 
within the Sox gene groups enables alterations in the amino acid sequences and changes 
to their functional role over evolutionary time (Kamachi and Kondoh, 2013). Sox family 
of proteins require binding of a transcription factor partner (Figure 3A) to an adjacent 
site on the DNA as a means to induce transcriptional activation or repression and to 
establish Sox-DNA complexes, increasing stability and regulating transcriptional activity 
(Kamachi and Kondoh, 2013).  
Although Sox Group A is characteristic of mammalian Y-chromosomes and 
contains only Sry, groups B to F are distinguishable in invertebrates (Figure 2C) 
(Kamachi and Kondoh, 2013). Group B is sub-divided into B1 and B2 that differ in 
neural and sensory tissue targets, specification of the vertebrate brain, and are involved in 
3
Figure 2: (A) Phylogenic tree of the high mobility group (HMG) domains of the mouse including the members within 
multiple evolutionary Sox groups. (B) Alignment of the Sox HMG domains. The sequences of 20 mouse Sox proteins 
arranged by the relationships of their sequence containing 79 amino acids. Conservation of amino acid sequences are defined 
by their logos. (C) The diversity of mouse Sox proteins organized by their domain structures demonstrating the various Sox 
groups. The basic structures remain conserved amongst members within each group. (Adapted from Kamachi, Y., and 
Kondoh, H. (2013). Sox proteins: regulators of cell fate specification and differentiation. Development 140, 4129–4144.)    
A 
B 
C 
A
B
C
4
Figure 3: (A) Representation of Sox-partner complexes demonstrating DNA-binding and 
subsequent function. (B) Sox9 homodimer-binding sequences that are demonstrated to bind to 
DNA enhancers of collagen and related genes. Sox9 homodimer-binding sequences differ from 
the Sox consensus sequence at both sites. (C) Sox9-partner complexes that mediate 
developmental processes. Specifically, Sox9 induction is activated via Sry-Sf1 during male gonad 
development. (D) Sox9 dimerization with an identical Sox9 protein to employ a homo-dimer and 
initiate the dimerization of  the SoxD group proteins; Sox5/Sox6, to bind to a nearby DNA site 
during chondrocyte development. Acan, aggrecan; Col9a1, collagen, type IX, α1; Col10a1, 
collagen, type X, α1; Col11a2, collagen, type XI, α2; Dppa4, developmental pluripotency 
associated 4; Fbxo15, F-box protein 15; Fgf4, fibroblast growth factor 4; Pou5f1, POU domain, 
class 5, transcription factor 1; Utf1, undifferentiated embryonic cell transcription factor 1; Amh, 
anti-Mullerian hormone; Pgds, prostaglandin D synthase; Sf1, steroidogenic factor 1; Sox, SRY-
related HMG-box. (Adapted from Kamachi, Y., and Kondoh, H. (2013). Sox proteins: regulators 
of cell fate specification and differentiation. Development 140, 4129–4144.)  
C D 
A B 
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neural plate development (Okuda et al., 2006; Uchikawa et al., 2011). B2 also differs in 
that it contains a transcriptional repression domain unlike B1 that exhibits an activation 
domain in the C-terminal (Kamachi and Kondoh, 2013). Sox21 of the Sox B2 Group 
represses expression to promote neurogenesis (Matsuda et al., 2012). Sox Group C is 
involved in governing reproduction and sexual development and along with Sox Group E 
and F are similar in organization to Group B1 (Kamachi and Kondoh, 2013). Sox Group 
D contains a long N-terminal sequence with a Leucine-zipper motif containing repetitive 
Leucine residues (Landschulz et al., 1988). It is followed by a coiled-coil domain as a 
result of a glutamine-rich region as a means to dimerize with other Sox D proteins 
mediating both homo or hetero dimerization (Kamachi and Kondoh, 2013). This differs 
from Sox Group E that contains a unique defined self-dimerization domain important 
during cartilage formation and sex determination in early embryonic development 
(Kamachi and Kondoh, 2013). Group F has been associated with vascular and 
hematopoietic development and contains an activation domain significantly closer than 
Group C and E to the N-terminus (Chung et al., 2011). Both Sox Group G and Sox Group 
H are specific to mammals with Group G possessing the relatively smallest construct and 
Group H (Sox 30) sustaining the largest Sox construct (Meeson et al., 2007; Osaki et al., 
1999).        
1.3 The Sox Group E Family of SOX Proteins: The SOX9 Transcription Factor 
The Sox Group E family of human SOX proteins including SOX8, SOX9, and 
SOX10 have been shown to bind to DNA as both a monomer and dimer (Bernard et al., 
2003). These proteins are identified by their capability to cooperatively dimerize in a 
fashion that is DNA-dependent on a consensus site; (A/T)(A/T)CAA(A/T)G (Harley et 
6
al., 1994). Such dimerization is reliant on approximately 40 amino acids N-terminal to 
the HMG domain. This is in stark contrast to SOX5, SOX6, and SOX11 that are part of 
the Group D class of proteins whereby dimerization dependency relies on a Leucine 
zipper motif also in a DNA-dependent manner (Takamatsu et al., 1995). More 
importantly, the differentiation between monomeric or dimeric binding to a variety of 
promoters can specialize the function of SOX9 during development (Bernard et al., 
2003).  
SOX9 is an approximately 60kDa transcription factor protein containing 507 
amino acids. Its structure (Figure 8A) contains an N-terminal dimerization domain 
followed by an HMG domain flanked by two nuclear localization signals (NLS). The C-
terminal is comprised of a PQA rich region followed by a transcriptional activation 
domain. The crystal structure of the HMG domain of SOX9 complexed with DNA 
(SOX9-DNA) at a single DNA site demonstrates the affinity for SOX9 to bind and bend 
DNA (Figure 4). SOX9 is a transcription factor that recognizes the sequence 
CCTTGAG. It can form either a monomeric or dimeric structure to determine its 
subsequent function by binding to specific partners including an identical SOX9 protein 
forming a homodimer, or an alternative binding partner forming a heterodimer, and 
activating targeted genes (Figure 3C & 3D) (Kamachi and Kondoh, 2013). The 
alterations between monomeric and dimeric binding states and alternative SOX9 
binding partners assume specific confirmations depending on the complex formed 
that elicit specific transcriptional regulation (Kamachi and Kondoh, 2013). As a 
result, the binding sequences differ from the consensus-binding site between a single 
factor and SOX9-partner complexes (Figure 3B).  
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Figure 4: Crystal structure of the HMG domain containing three alpha helices of the transcription 
factor SOX9 bound to DNA (SOX9-DNA) of Homo sapiens at 2.77 A resolution (Recreated from 
PDB ID: 4EUW).   
8
1.4 A Monomeric SOX9: Sex Determination  
The role of SOX9 in sex determination was first revealed post-discovery of the 
sex-determining region Y (SRY) protein responsible for the initiation of male sex 
determination in humans. SOX9 was identified via genetic analysis of patients with 
human Campomelic dysplasia (CD) whereby XY individuals with heterozygous SOX9 
mutations demonstrated male-to-female sex reversals (Kamachi and Kondoh, 2013). A 
knockout of SOX9 leads to male gonad defects and XY gonad dysgenesis (Sekido and 
Lovell-Badge, 2008; Wilhelm et al., 2007). In mice, Sry is transiently expressed in 
supporting somatic cells of the gonads that have yet to be determined between embryonic 
day 10.5 to 12.5 (Kamachi and Kondoh, 2013; Sekido and Lovell-Badge, 2008). During 
this period of development, Sry expression will trigger the differentiation of these 
somatic cells into Sertoli cells (Figure 5A) (Kamachi and Kondoh, 2013). Using the 
testis-specific enhancer (Tes) of Sox9, synergistically Sox9 and Steroidogenic factor 1 
(Sf1) are directly activated as a result of Sry (Kamachi and Kondoh, 2013). Once 
expression of Sox9 is activated passed a critical threshold level, the expression levels are 
maintained in the Sertoli cells with a positive-feedback loop (Kamachi and Kondoh, 
2013). The auto-regulated positive feedback mechanism of Sox9 is maintained via Sox9 
activating the Tes enhancer in a cooperative manner with Sf1 (Eggers et al., 2014; 
Kamachi and Kondoh, 2013). Sox9 as a monomer can then activate other genes 
responsible for testis development including prostaglandin D synthase (Pgds) (Kamachi 
and Kondoh, 2013).  
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Figure 5: (A) The pathway regulating testes development and differentiation in part requires 
that Sry is transiently expressed in the bipotential gonad with the highest level of expression 
during development at embryonic day 12.5. This in turn increases the expression of Sox9 in the 
developing testes. Sox9 maintains a positive feedback loop by way of auto-regulation and under 
the influence of co-factors Sry, Nr5a1, Dax1, Fgf9, and many other genes. (B) The two 
pathways leading to either testes or ovary development is partially dependant on the regulation 
of Sox9 along with an array of genes and proteins. Foxl2, Rspo1, Wnt4, and Ctnnb1(β-catenin) 
genes contribute to inhibition of Sox9 and Fgf1 that in turn inhibit the development of ovaries by 
then suppressing the expression of Rspo1 and Wnt4-Ctnnb1. This process is maintained by other 
factors throughout the adult life. (Adapted from Eggers, S., Ohnesorg, T., and Sinclair, A. 
(2014). Genetic regulation of mammalian gonad development. Nat Rev Endocrinol 10, 673–
683.)        
A 
B 
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SOX9 plays a pivotal role in male sexual development and male sexual 
differentiation due to the regulation of the anti-Müllerian hormone (AMH) activated by 
the cooperative action of SOX9 and Sf1 (Kamachi and Kondoh, 2013). Cooperative 
binding occurs when the binding at one site increases the rate at which binding occurs at 
a second site between identical or non-identical proteins. AMH is strictly regulated in 
male-sex determination during embryonic development via reversion of the Müllerian 
duct. Although lost in males, this duct is associated with the uterine tubes, uterus, cervix, 
and vagina in females (De Santa Barbara et al., 1998). It is Sf1, located in the AMH 
proximal promoter that is essential for AMH gene activation (De Santa Barbara et al., 
1998). SOX9 can produce AMH in Sertoli cells to inhibit the development of the female 
reproductive system (Figure 5B) (De Santa Barbara et al., 1998). Rather, it promotes the 
development of male sexual organs (De Santa Barbara et al., 1998). This process is 
initiated when the Testis determining factor encoded by SRY activates SOX9 by binding 
to the enhancer sequence upstream of the gene (De Santa Barbara et al., 1998). SOX9 
activates a glia-activating factor identified as Fibroblast growth factor 9 (Fgf9) to enable 
development of the testis cord and increase Sertoli cell count (Kamachi and Kondoh, 
2013). In addition, SOX8 is expressed when SOX9 is up-regulated and plays a role in the 
maintenance of testis function during later stages of development (Kamachi and Kondoh, 
2013).  
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1.5 A Dimeric SOX9: Chondrogenesis   
The role of SOX9 is not limited to sex determination but rather plays a significant 
role in early development, programmed cell death, as well as maintenance of the cell 
cycle. Its function in early cartilage and skeletal development was first reported as a 
result of heterozygous human SOX9 mutations as a cause for the skeletal disorder; CD 
(Coustry et al., 2010; Kamachi and Kondoh, 2013). Such heterozygous mice suffer 
perinatal mortality due to abnormal skeletal development (Bi et al., 2001; Kamachi and 
Kondoh, 2013). Specifically, during chondrogenesis; the process by which cartilage is 
formed, SOX9 expression levels are high and maintained throughout the chondrocyte 
lineage (Kamachi and Kondoh, 2013; Ng et al., 1997; Zuscik et al., 2008). SOX9 is 
critical for multi-step chondrocyte differentiation, function, and has been deemed as a 
master regulator in controlling the secretion of cartilage matrix proteins (Hino et al, 
2014). In addition, the expression of SOX9 is present and essential throughout multiple 
stages of cartilage formation (Figure 6A) including the commitment process from an 
undifferentiated mesenchymal cells to osteochondroprogenitor cells, and further 
downstream to condensed mesenchymal cells, differentiated chondrocytes, and 
proliferating chondrocytes (Akiyama et al., 2002) (Zuscik et al., 2008). This 
eventually leads to the formation of hypertrophic chondrocytes and finally calcified 
cartilage (Akiyama et al., 2002). SOX9 is present within distinct cell types, time 
points, and located in the radial cellular zone during the process of chondrogenesis 
(Figure 6B & 6C). However, SOX9 inhibits the transition from proliferating to 
hypertrophy cells (Akiyama et al., 2002). Sox9 knockdowns lead to chondrogenesis 
defects including congenital diseases like CD as a result of either activation or 
repression of targeted genes such as Col10a1 (Dy et al., 2012; Leung et al., 2011).  
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A 
Figure 6: (A) Model for endochondral bone development. SOX9 is expressed and functions as 
a homo-dimer during multiple stages of the chondrocyte differentiation pathway. This includes 
the participation of an array of co-factors. (B) Distinct cellular zones whereby Sox9 is present in 
the radial zone (RZ). (C) Model for the process of chondrogenesis and the differentiation of 
chondrocytes. (Adapted from Zuscik, M.J., Hilton, M.J., Zhang, X., Chen, D., and O'Keefe, R.J. 
(2008). Regulation of chondrogenesis and chondrocyte differentiation by stress. J. Clin. Invest. 
118, 429–438.) 
A B 
C 
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The DNA binding site sequences for Sox9-partner complexes differ from the 
consensus sequences for single factors binding to DNA due to a specific confirmation by 
the complex to elicit transcriptional regulation. During the process of chondrogenesis, the 
Sox9 homodimer binding sequences differ from the Sox9 consensus sequence at both 
sites (Figure 3B) (Kamachi and Kondoh, 2013). Its expression profile is similar to that of 
type II collagen gene Col2a1 that encodes the major cartilage matrix protein (Lefebvre et 
al., 1997). The binding of SOX9 is a potent activator to this particular intronic enhancer 
and is essential for the activation of the Col2a1 gene (Kamachi and Kondoh, 2013; 
Lefebvre et al., 1997). More importantly, SOX9 directly regulates an array of collagen 
genes (Lefebvre et al., 1997). Furthermore, Sox9 and Col2a1 are expressed in cells 
during chondrogenesis (Zhao et al., 1997). Other SOX proteins including SOX5 and 
SOX6 of the Sox D family also mediate the entire process (Akiyama et al., 2002). SOX9 
is essential for the expression of SOX5 and SOX6 (Akiyama et al., 2002). Strong 
activation of the minimal enhancer Col2a1 only occurs when SOX9 and proteins SOX5 
and SOX6 bind to several sites in the enhancer (Han and Lefebvre, 2008; Kamachi and 
Kondoh, 2013). This has been defined in literature as a “Sox trio” that corresponds to a 
SOX9 homodimer with multiple SOX5/6 dimers binding to an adjacent DNA site 
(Kamachi and Kondoh, 2013).  In the presence of normal SOX9 levels, a double 
knockout of SOX5/6 leads to a lack of chondrogenesis, while an individual knockout of 
either SOX5 or SOX6 leads to mild skeletal abnormalities (Kamachi and Kondoh, 2013; 
Smits et al., 2001). This suggests that there lies some form of cooperation between SoxD-
SoxE families that enables an important molecular mechanism regulating chondrogenesis 
(Kamachi and Kondoh, 2013). More importantly, the SOX9 dimer-binding sequences 
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present in enhancers of genes that regulate chondrocyte development differ from SOX 
consensus binding sequences in both sites (Kamachi and Kondoh, 2013).  
1.6 The Importance of the Dimerization Domain  
The dimerization domain is a region of amino acids defined by its affinity to 
homodimerize or heterodimerize depending on the nature of the subunits to ultimately 
control gene expression and cell function (Feuerstein et al., 1994). Studies have 
demonstrated that patients who harbor mutations including substitutions and in-frame 
deletions preceding the HMG domain, i.e. the dimerization region, instigate a direct onset 
of semi lethal skeletal anomalies characterized in CD, male-female sex reversal, and 
developmental defects in cartilage formation (Lefebvre et al., 1997; Sock et al., 2003). 
One of the first mutations outside of the HMG domain associated with XY male patients 
that were not sex-reversed but diagnosed with CD was the A76E mutation.  It is the 
structural conformational change due to dimerization that enables activation of promoters 
through dimeric binding sites, however this is lost in two mutant SOX9 patient studies 
(Sock, 2003). During cartilage formation cartilage specific promoter sequences like pro-
α1 (II) collagen gene Col2a1 contain HMG domain binding sites that are inverted 
(Lefebvre et al., 1997). These sites are spaced a couple of base pairs apart and maintain 
an affinity for two closely adjacent SOX9 proteins (Lefebvre et al., 1997).  
The dimerization domain of SOX9 is suggested to play a critical role in 
modifying the Col2a1 chromatin to initiate transcription (Lefebvre et al., 1997). DNA 
binding differs between wildtype SOX9 and a SOX9 dimerization mutant such that the 
wild-type SOX9 dimeric complex increases at a slower rate with a sigmoidal progression 
(Lefebvre et al., 1997). This differs from a mutated dimerization domain that increases 
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linearly (Lefebvre et al., 1997). Stability of DNA-SOX9 complexes is not affected by the 
presence of an active dimerization domain and transcription is activated however, 
chromatin remodeling is hindered in the dimerization domain mutant (Lefebvre et al., 
1997). Ultimately, the dimerization domain enables a stronger activation Col2a1 
promoter/enhancer-luciferase than the mutant SOX9 but interactions with the chromatin 
are unaffected (Lefebvre et al., 1997).  
1.7 HMG Proteins Bind and Bend DNA  
DNA bending by the HMG-box of HMG proteins like SOX9 are established on 
the basis of HMG-box-DNA structures. The important characteristics of the HMG-box-
DNA complex is that bulky hydrophobic amino acids present in the HMG-box 
intercalates between successive base-pairs within the minor groove of DNA (Stros, 
2010). Together with partial unwinding and winding of the minor groove elicits bending 
toward the major groove of DNA (Stros, 2010). The contact with the minor groove of the 
DNA double helix forces the DNA to bend to and L-shape angle varying from 30° to 
110° (Figure 7) (Lefebvre et al., 2007). The inserted hydrophobic residues of the HMG-
box flanked by basic residues are conserved and bind to the phosphodiester bond of DNA 
to create stability in the protein-DNA complex (Stros, 2010). Within the HMGB1/2 there 
contains two boxes defined as A and B. HMG-box B has a greater responsibility for 
bending DNA than A, as A lacks a primary intercalating residue (Stros, 2010). The 
residues generally responsible are Phenylalanine and Isoleucine.  DNA bending by non-
sequence-specific proteins differ from sequence-specific proteins such that non-specific 
proteins are associated with multiple hydrophobic residues at two sites in DNA unlike 
sequence-specific proteins whereby only one intercalation residue is observed (Stros, 
2010). 	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Figure 7: The SOX HMG Box domain bound to a DNA double helix and inducing a L-
shaped bend in the DNA that ranges from 30° to 110°. (Adapted from Lefebvre, V., 
Dumitriu, B., Penzo-Méndez, A., Han, Y., & Pallavi, B. (2007). Control of cell fate and 
differentiation by Sry-related high-mobility-group box (Sox) transcription factors. The 
International Journal of Biochemistry & Cell Biology, 39(12), 2195–2214. http://doi.org/ 
10.1016/j.biocel.2007.05.019)  
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For example, NHP6A is a chromatin-associated protein in Saccharomyces 
cerevisiae from the HMG1/2 family of non-specific DNA binding proteins (Allain et al., 
1999). The NMR-based model of the NHP6A-DNA complex structure illustrates the 
HMG domain of the protein positioned onto the minor groove of the DNA by which the 
distortion site contains two kinks in the DNA where Methionine and Phenylalanine are 
inserted and deemed critical for bending (Allain et al., 1999).  A similar crystal structure 
is confirmed with a non-histone HMG chromosomal protein from Drosophila 
melanogaster whereby HMG-D binds a DNA duplex in a non-sequence-specific manner 
(Murphy et al., 1999).   
1.8 The Functional Significance of DNA Bending  
Relevant to functionality, the importance of DNA bending is observed by virtue 
of in vitro assays (Stros, 2010). Mutations of these critical intercalating residues 
demonstrate a decrease in mobility in these residues and in HMGB1 living cells 
preventing binding to chromatin (Stros, 2010). Furthermore, these residues are required 
for stimulation of progesterone receptor transcriptional activity as well as the expression 
from the human topoisomerase IIα gene promoter in vivo due to the impairment of DNA 
bending (Stros, 2010). It enables looping as well as flexibility in DNA by transiently even 
binding to DNA (Stros, 2010). This has been confirmed by electron microscopy and dual 
laser optical tweezer experiments (Stros, 2010). Aside from specific binding, random 
binding to DNA for a short period of time enables the DNA to bend with more fluidity 
and local flexibility at specific binding sites. Such binding could contribute to an increase 
in cooperativity.  Combined, bending and looping can provide a mechanism for proteins 
to promote activity of gene promoters by the enhancement of binding of transcription 
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factors as well as spatially guiding regulatory sequences into close proximity (Stros, 
2010).  
Alternatively, the anticancer activity of cis-diamminedichloroplatinum(II) 
(cisplatin) is a product of its ability to damage DNA by bending and unwinding the 
duplex (Ohndorf et al., 1999). The structural change exposes sites preferable for HMG 
domain proteins to bind to the cisplatin-modified DNA to mediate antitumor properties of 
the drug (Ohndorf et al., 1999). X-ray studies revel that the HMG-domain of the protein 
binds to the widened minor groove of the DNA and a specific Phenylalanine residue at 
position 37 intercalates into a hydrophobic notch (Ohndorf et al., 1999). In addition, 
binding is significantly reduced in a substitution mutation with Alanine at position 37 
(Ohndorf et al., 1999). The HMG-box domain in human SRY (hSRY) male-sex 
determining factor, binds DNA in a sequence-specific manner of the minor groove of 
DNA initiating a substantial bend (Murphy et al., 2001). Most of the point mutations that 
result in 46XY sex reversals are within the HMG domain (Murphy et al., 2001).The 
clinical mutation M64I corresponds to M9I in the HMG of hSRY and reduces the extent 
of bending of DNA from 54° in the wildtype to 41° in the mutant (Murphy et al., 2001). 
This is due to changes in the roll and tilt angles in the base pair interactions with residue 
9 and only partial intercalation of Isoleucine 13 as per the 3D model studied via NMR 
spectroscopy (Murphy et al., 2001). The bend in the wildtype is a result of steric 
repulsion in the sugar of the second adenine combined with the bulkiness of Methionine 9 
(Murphy et al., 2001). The position of Methionine 9 is fixed by a hydrogen bond with the 
guanidino group of Arg17 (Murphy et al., 2001). When Methionine is replaced by 
Isoleucine, the hydrogen bond is lost due to the presence of a less bulky methyl group in 
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isoleucine and braces the sugar moieties thereby decreasing the roll and tilt angle 
(Murphy et al., 2001).  
1.9 SOX Proteins Bend DNA to Elicit Function  
The activity of SOX proteins via DNA bending is an essential factor for the 
regulation of gene expression. Studies have well characterized the ability of SOX 
proteins to first bind and subsequently elicit a bend in the DNA changing the structure of 
the DNA and the protein complex. Mouse Sox2 participates in the transactivation of the 
fibroblast growth factor (Fgf4) gene in the inner cell mass of the blastocyst (Scaffidi and 
Bianchi, 2001). Mutations to either the HMG box of Sox2 or base-mutations to the Fgf4 
enhancer resulted in less bending of the DNA from 80° to 42° or 0° (Scaffidi and 
Bianchi, 2001). Reduced bending resulted in a decrease in transcription activity for all 
mutants except for one Sox2 HMG mutant whereby reduced bending resulted in a more 
powerful transactivation in comparison to the wildtype protein (Scaffidi and Bianchi, 
2001).   
The dynamic properties of protein-DNA binding via the HMG box are in part due 
to the nature of the sequence-specific (SS) or non-sequence-specific (NSS) HMG box 
proteins (Dragan et al., 2004). DNA recognition sequences differ in stability. SS proteins 
are identified as partially unfolded at room temperature however when in complex with 
DNA stabilizes and results in cooperation (Dragan et al., 2004). The difference between 
SS and NSS are that SS are formed with an enthalpy close to zero and a negative heat 
capacity unlike NSS that forms with a high positive enthalpy and positive heat 
capacity(Dragan et al., 2004). The complex formed between the SS HMG box-DNA 
complexes are a more tightly compact interface via extensive van der Waals contact 
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points between apolar groups than NSS HMG box-DNA complexes (Dragan et al., 2004). 
The bending of DNA via the NSS-DNA interaction is highly dependant on the 
electrostatic component of the binding energy (Dragan et al., 2004). Unlike DNA 
bending by SS-DNA complexes that are highly driven by the non-electrostatic 
component (Dragan et al., 2004).  
The existence of the HMG box enables Sox5 to induce a large bend in double 
helix DNA to regulate the function of gene expression during the post-meiotic phase of 
spermatogenesis (Connor et al., 1994). DNA bending by Sox5 is demonstrated with 
circular permutation assays (Connor et al., 1994). Annealed synthetic nucleotides 
containing the Sox5 binding site were constructed via an electromobility shifts assay 
(EMSA) and the center of DNA bending to the Sox5 binding site was mapped to 
visualize the quantification of Rbound/Rfree against flexure displacement (Connor et al., 
1994). Flexure displacement was defined as the distance of the centre of Sox5 in vitro 
binding motif from the 5’ end of the probe divided by the total length of the probe 
(Connor et al., 1994). As expected, the assay revealed that the minimum centre of 
bending was located to the AACAAT motif (Connor et al., 1994).  The bending of DNA 
via Sox proteins may play a critical role in the assembly of transcriptional 
enhanceosomes (Lefebvre et al., 2007). These are defined as the higher-order protein 
complexes assembled at the enhancer that regulate target gene expression (Lefebvre et 
al., 2007).    
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Circular permutation assays using circular permutated probes have been at the 
forefront of demonstrating that the Sox Group E family of proteins bind and bend DNA. 
The Col2a1 enhancer has demonstrated to bend by the specific binding of SOX9 by 
mapping the flexure displacements (Lefebvre et al., 1997).  There is a correlation 
between the expression of Col2a1 and SOX9 in chondrogenic cells that is important for 
cartilage formation during embryonic development (Lefebvre et al., 1997). Yeast-two-
hybrid screens have demonstrated that Sox8 and Sox10 proteins of the Group E family of 
Sox proteins posses DNA-binding and DNA-bending for the architectural function of Sox 
proteins on their target gene promoter (Wissmüller et al., 2006). The stabilization of the 
Sox protein when bound to DNA is a product of the Sox protein initiating varying 
degrees of bending in the DNA as a result of a flexible angular surface of the L-shaped 
HMG Box domain that becomes fixed upon the binding to DNA (Lefebvre et al., 2007). 
The dual nature of the protein-DNA complex is complimentary and important as SOX 
instructs the DNA how to bend, while the DNA instructs the SOX protein on how to 
complete its tertiary fold (Lefebvre et al., 2007). As a result, there is an enhanced stability 
formed by the complex and novel functionality (Lefebvre et al., 2007). Cooperative 
binding of Sox10 to a dimeric binding site C/C′ is dependent on 40 amino acids 
preceding the HMG (Peirano and Wegner, 2000). Sox10 wildtype and spacing mutants 
were studied to determine the effect on cooperative binding. Spacing variants of 
sequences inserted between site C and site C′ demonstrated that increasing the sequence 
length increases the bending angle by up to 20° (Schlierf et al., 2002). Consequently, an 
increase in sequence length decreases cooperativity and quantity of bound dimer (Schlierf 
et al., 2002). All three SOX E proteins have overlapping expression patterns during 
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embryogenesis that could confer to functional redundancy but mainly control seemingly 
unrelated developmental processes in different tissues (Wissmüller et al., 2006).    
1.10 Clinical Role of SOX9 
SOX9 expression is a contributing factor in several well-studied developmental 
malformations and diseases (Table 1). The absence of SOX9 has been associated with 
CD, a form of skeletal dysplasia. CD has distinctive dysmorphological characteristics 
including cleft palate, bowing of long bones, short stature, instability of the cervical spine 
leading to cord compression, scoliosis, and club feet (Mansour et al., 1995). Infants are 
known to die as a neonate (Mansour et al., 1995). With only a single functional copy of 
the SOX9 gene defective cartilage primordia and premature skeletal mineralization is 
prevalent (Bi et al., 2001). The SOX9 gene is located at 17q24 on chromosome 17 
consisting of approximately 5400 bases in size. SOX9 has also been identified to play a 
role in sex reversal in humans during early embryonic development (Foster, 1996). 
Studies confirm that such reversal is a result of mutations to the SRY gene in a XY 
individual affecting SOX9 expression levels and results in a sex-reversed female 
phenotype (Foster, 1996). Consequently, mutation studies have confirmed de novo 
mutations in the SOX9 gene in patients with both autosomal sex reversal and CD 
(Foster, 1996; Kwok et al., 1995). SOX9 participates in a multitude of developmental 
processes including the growth plate of endochondral bones, hair bulging via hair 
follicle stem cells and early skin morphogenesis required for formation of hair 
follicles and sebaceous glands (Fantauzzo 
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Table 1: The array of tissues and purposes of activation of SOX9 with associated binding partners 
as well as monomeric or dimeric binding sites of SOX9 in order to activate known targeted genes. 
SOX9 knockouts lead to changes in phenotypes and associated congenital human diseases during 
embryonic development.      
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et al., 2012; Nowak et al., 2008; Vidal et al., 2005; 2001). Knockouts of SOX9 lead to 
alopecia or hair loss from the scalp and hypertrichosis; a SOX9 dysregulation (Nowak et 
al., 2008). 
SOX9 is a significant player in the regulation of the state of stem cells. It is 
identified as a key contributor to liver regeneration, fibrosis, formation of liver duct cells, 
and tracing of hepatocytes post injury (Ein et al., 2014; Furuyama et al., 2011). This 
diverse protein contributes to distal tip lung cell formation (Rawlins, 2011). Pancreatic 
progenitors lead to the development of exocrine pancreatic duct cells with Sox9 genetic 
deletions conferring to a loss of pancreatic progenitors, intestinal stem, and Paneth cells 
(Furuyama et al., 2011; Kopp et al., 2011; Sato et al., 2011; Seymour et al., 2007). SOX9 
expression is associated with the development of retinal progenitor cells (RPCs) with 
genetic deletions facilitating the loss of the potential for stem cell differentiation in 
Müller glial cells (Poché et al., 2008). Mammary stem cell (MaSC) activity is blocked 
upon the inhibition of either Sox9 or Slug in mammary epithelial cells (Guo et al., 2012). 
Conversely, transient co-expression of either from an exogenous source enables the 
conversion of differentiated luminal cells to MaSCs such that Sox9 and Slug 
cooperatively determine the state of MaSCs (Guo et al., 2012).   
The expression of SOX9 is essential during neuronal development. Normal otic 
placode development can become impacted by otic placode invagination defects when 
Sox9 is knocked out (Barrionuevo et al., 2008). Such tissue specific knockdowns 
also lead to failure of neural stem maintenance from the development of neural stem 
cells including the determination of glial fate in the developing spinal cord (Cheng et al., 
2009; Scott et al., 2010; Stolt et al., 2003). This includes impaired gliogenesis during 
defective glial 
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progenitor development (Kang et al., 2012; Stolt et al., 2003). Sox9 is expressed in the 
developing CNS and maintains the multipotency of stem cells (Cheng et al., 2009) 
(Fantauzzo et al., 2012). From the Group E family, both Sox9 and Sox10 play a major 
role in the formation of oligodendrocyte progenitors (Pozniak et al., 2010; Stolt et al., 
2003; 2002; 2006). Oligodendrocytes modulated by Sox D proteins are known to target 
the suppressor of the fused myelin basic protein however deficits in Sox9 lead to a loss of 
oligodendrocytes (Pozniak et al., 2010; Stolt et al., 2002; 2003; 2006). In the cranial 
neural crest, there is a cooperation between Sox9 with Ets1 and cMyb to activate the 
Sox10 gene in a Sox9-dependant manner (Agarwal et al., 2011; Betancur et al., 2010). 
When phosphorylated, Sox9 also plays a critical role in neural crest formation however a 
deficiency or lack of Sox9 contributes to the loss of neural crest delamination via 
downstream regulation by bone morphogenetic protein (BMP) and canonical Wnt 
(Betancur et al., 2010; Cheung and Briscoe, 2003; Liu et al., 2013). This includes the 
cooperative action of Sox9, Snail2, and Protein Kinase A (PKA) (Sakai et al., 2006).  
The role of SOX9 in cancer is extremely diverse including its up-regulation in 
tumors associated with pancreatic cancer and high expression in gastric cancers. SOX9 
regulates miR-32 in osteosarcoma and can aid as a marker in its potential progression and 
prognosis (Camaj et al., 2014; Choi et al., 2014; Xu et al., 2014; Zhu et al., 2013). In 
esophageal cancer, the ability of stem cell properties to be acquired has demonstrated to 
be dependant on the expression of SOX9 in a YAP-1 driven manner (Song et al., 2014).  
SOX9 expression mediated by Rac1 has been demonstrated in inner meniscus cells 
(Kanazawa et al., 2014). More importantly, meniscus cells have been studied as a donor 
for tissue engineering (Nakata et al., 2001).    
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1.11 SOX9 Therapeutic Role 
The expression of SOX9 is altered in tumorigenesis such as osteosarcoma. 
Upregulation of SOX9 was evident in 72% of aggressive human osteosarcoma 
tissues and expression further increases during advanced clinical stages indicating its 
fundamental role in the progression of bone cancer (Zhu et al., 2013). Such advanced 
stages include distant metastasis and a reduced response to chemotherapy (Zhu et al., 
2013). This suggests that SOX9 can be used as a tool for early detection and 
prognosis of osteosarcoma and a target for optimal clinical treatment (Zhu et al., 
2013). Small molecules could be developed to target the binding of SOX9 or compete 
for binding on DNA and prevent subsequent clinical stages of cancer progression. 
Similarly, adenovirus with down regulated Sox9 can be injected into tumors to 
prevent tumor growth. Likewise, meniscus cells have been described as a 
candidate for tissue-specific engineering (Nakata et al., 2001). Meniscus cells are 
critical for fibrocartilaginous tissue in the knee joint as well as other joint stability 
mechanisms such as load distribution (Adesida et al., 2007). When abolished, there is a 
higher incidence of osteoarthritis (Adesida et al., 2007). SOX9 expression has been 
associated with an increase in oxygen-tension that is correlated to the suppression of 
cartilage-like matrix formation (Adesida et al., 2007). The high incidence of SOX9 
expression could be used as a marker for the onset of osteoarthritis as well as 
maintaining the viability of meniscus cells for tissue engineering as these cells could 
be cultured, propagated, and seeded onto a collagen scaffold (Nakata et al., 2001).           
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1.12 Thesis Overview and Objective 
This study features a model for the interaction of the dimerization domain with 
the HMG domain of two identical SOX9 [71/184] constructs. The two wildtype 
constructs featured in this study are SOX9 [71/184] containing both the dimerization 
domain and HMG domain and SOX9 [101/184] that contains only the HMG domain 
(Figure 8B). This study utilizes two different DNA constructs; a single site S9WT and 
CC36; a 36 bp double site palindrome  (Figure 8C & 8D). CC36 differs from a canonical 
sequence at the first position and is similar to the first C binding site in the tandem C/C’ 
region of the Po gene promoter that binds to SOX10 (Peirano and Wegner, 
2000). SOX9 proteins bind to CC36 via a primary consensus and secondary non 
consensus site that are inverted palindromes comparable to the Col2a1 gene. SOX9 
will play a role in cooperative DNA binding via its dimerization domain.
Upon examining the structural interaction between DNA and the DNA binding 
protein SOX9, the hydrophobic platform and formation of a helix bundle can be defined. 
This study can provide insight into the sequential process of DNA binding, the 
relationship between the dimerization domain and HMG domain, and if dimerization 
affects the affinity of DNA-binding. This also includes whether the stability of SOX9 is 
affected by the presence of the dimerization domain. In addition, four mutations of SOX9 
[71/184] at A118E and A119E within the first alpha helix (α1) of the HMG domain and 
L142Q and L145E within the second and linker region of the second (α2) and third (α3) 
alpha helix (Figure 9A) can test the role of the conserved di-alanine site and conserved 
leucines characteristic of the Sox E family of proteins (Figure 9B) can be determined via 
mutagenesis and biological assays. Comprehensively, conducting such experiments can   
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assist in determining if co-operative binding can play a role such that the binding of 
one SOX9 [71/184] protein to one DNA site facilitates binding of a second SOX9 
[71/184] to a second adjacent site. This can establish a binding mechanism by 
characterizing the affinity for the dimerization domain with the HMG domain and 
develop a novel binding structural model between SOX9 with a double-site DNA.       
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Figure 8: (A) Domain organization of SOX9. (B) Wildtype SOX9 [71/184] and [101/184] 
constructs used to conduct this study. (C) Single site DNA S9WT baring one canonical 
binding site. (D) A 36 bp palindromic oligonucleotide; CC36, used with the inverted 
heptameric binding sites indicated within the boxes (Courtesy of Dr. Logan Donaldson).       
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Figure 9: (A) Four generations of Human SOX9 mutants. Boxes indicate the sequence 
boundaries of the dimerization domain (α0) as well as the HMG domain (α1, α2, α3) that was 
determined from the crystal structure of the SOX9:DNA complex (PDB: 4EUW). The 
PSIPRED secondary structure prediction is located above the sequence.  (B) The sequence 
alignment of the HMG domains of SOX8, SOX9, and SOX10 that are within the Sox E 
Group of proteins as well as two non-dimerizing proteins; SRY and SOX18. The black 
highlights the regions whereby substitutions prevent dimerization while yellow highlighting 
denotes the regions that substitutions have no affect on dimerization. Green highlighting is 
indicative of substitutions that affect protein expression, stability, or folding and directly 
could inhibit the conducting of further experimental assays. The di-alanine residiues in the 
first alpha helix and two leucines in the second alpha helix are characteristic of the Sox E 
family of proteins. (Courtesy of Dr. Logan Donaldson).  
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________________________________________________________________________ 
CHAPTER II  
EXPERIMENTAL METHODS 
________________________________________________________________________ 
2.1 Plasmid Construction  
A custom His6-SOX9 [71/184]gs DNA insert containing a NdeI/XbaI site was developed 
and purchased from GenScript Corporations. The insert was sub-cloned by a 
previous lab member into pUC57 and transformed via electroporation into E.coli 
BL21:DE3 (Novagen) to produce His6-SOX9 [71/184]gs. The cells were plated bearing 
Kanamycin resistance and grown overnight at 37°C. Individual colonies were sequenced, 
tested for expression, and prepared as individual glycerol stocks stored in the -80°C 
freezer for long term use.  
2.2 Protein Expression and Purification of His6-SOX9 [71/184]gs, His6-MBP-SOX9 
[101/184], His6-SOX9gs [71/184] A118E, His6-SOX9gs [71/184] A119E, His6-SOX9gs 
[71/184] L142Q, and His6-SOX9gs [71/184] A145E   
E.coli BL21 (DE3) cells expressing either His6-SOX9 [71/184]gs, His6-SOX9
[101-184], or His6-SOX9gs [71/184] mutants A118E, A119E, L142Q, and L145E were 
grown from individual 150mL overnight cultures in 500mL flasks of sterile LB 
supplemented with 50 µg/mL of Kanamycin and a fraction of the glycerol stock of the 
clones. The day cultures were grown at 37°C shaking at 200rpm in 1.5 liters of Luria-
Bertani (LB) broth supplemented with 50 µg/mL of Kanamycin in a 2.8 liter Allen flask. 
Day cultured cells were grown to an exponential phase reaching an optical density 
(OD600) of ~0.8-1.0. Cells were induced with 1.0mM IPTG (Wisent Inc) and the 
temperature was reduced to 25°C at 200rpm for a five hour post-induction period for 
32
soluble protein production. Following the post-induction period, cell pellets were 
collected by centrifugation at 7000rpm for 15 minutes at 4°C and placed in the -20°C 
freezer for a minimum of one hour. Cells were re-suspended over ice in 25mL of 6M urea 
supplemented with T300 (10mM Tris-HCl ph 8.0, 300mM NaCl). The re-suspended cells 
were lysed via three passes of compression at 15000psi using the Thermo Spectronic 
French® Pressure Cell Press. The cell lysate was kept over ice until centrifugation at 
17000rpm for 30 minutes at 4°C using a Beckman centrifuge. The soluble extract was 
then increased to a pH of 7.0 using Tris-HCl pH 7.5 and purified over a 10mL slurry of 
NI-NTA resin (Qiagen) column with an automated pump system (Amersham Biosciences 
Pump P-50). The column was primed in T300 at 2ml/minute and upon adding the lysate it 
was followed by sequential 50mL washes of 6M, 4M, 2M, and 1M urea supplemented 
with T300 at 3ml/minute. The column was further washed with 150mL of 15mM 
imidazole supplemented with T300 at 3ml/minute. The his-tagged SOX9 proteins were 
eluted with 20mM EDTA enriched with T300 at a rate of 2mL/minute following priming 
of the column with 20mM EDTA for 20 seconds. After collecting approximately 80mL 
of elution, 1mM PMSF was added. The elution was concentrated down via ultrafiltration 
using a Sartorius Stedim Biotech Vivaspin Turbo 15 5000 MWCO filter to 15mL of 
elution with gentile pipetting between each hour of spin at 5600rpm (Eppendorf 
Centrifuge 5430 R) at 4°C.  
The purified and concentrated His6-MBP-SOX9 [101/184] was placed in 1.5mL 
eppendorf tubes whereby 3-4 units of Sigma-Aldrich Human Thrombin T1063 was added 
to each tube containing 1mL of concentrated protein. Tubes were placed on a nutator 
overnight at 4°C as a means of liberating the SOX9 construct from the his-MBP tag. 4-
33
(2-Aminoethyl)-benzenesulfonyl fluoride HCL (AEBSF) (Bioshop) was added after 
16-18 hours to inactivate thrombin and prevent further cutting. For all SOX9 constructs
the 15mL of elution was spun down in 1.5mL eppendorf tubes at 4°C in a benchtop 
centrifuge (Thermo Scientific Sorvall Legend Micro 17 R Centrifuge) at 13300rpm for 10 
minutes to remove any precipitate. 5mL of the SOX9 construct elution was further 
purified at a time by fast protein liquid chromatography (FPLC) (Amersham pharmacia 
biotech AKTA FPLC) gel filtration using a Sephacryl S100 16/60 column (GE 
Biosciences) equilibrated with SOX9 buffer (10mM NaP, 100mM NaCl, 5mM EDTA, 
0.2% NaN3, and 1mM PMSF) ph 6.0 in order to prevent tryptophan proteases from 
attacking the protein. Fractions pertaining to the molecular weight of the protein of 
interest were then confirmed at the correct molecular weight on a 12% SDS gel using a 
protein ladder (Biorad Precision Plus Protein™ Dual Color Standards) and visualized 
with Fast SeeBand Single Step Protein staining solution (FroggaBio) on the Alpha 
Imager HP system (Alpha Innotech). Verified fractions were pooled and concentrated by 
ultrafiltration using a Pall Corporation Macrosep® Advance Centrifugal Device 3000 
MWCO filter for His6-MBP-SOX9 [101/184] and Sartorius MWCO 5000 for all other 
SOX9 constructs.  
Alternatively, if concentration of SOX9 proteins were being lost by the FPLC 
due to precipitation or affinity to the membrane of the column, dialysis provided a 
suitable alternative for buffer exchanging. SOX9 was concentrated down to 12mL and 
injected into a Thermo Scientific Slide-A-Lyzer ® Dialysis Cassette 3500 MWCO using 
as syringe as per protocol. The cassette was place in a 1L beaker filled with SOX9 buffer 
and a magnetic stirrer kept the cassette spinning for 1 hour at 4°C. This step was repeated 
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with fresh buffer after one hour for one final hour and then exchanged again with fresh 
buffer to spin overnight at 4°C. The following day, the buffer exchanged SOX9 was then 
removed from the cassette with a syringe and ready for testing. The molar concentrations 
for all SOX9 constructs were calculated from the A280 (Spectronic Unicam Genesys 
10uv) (using the extinction coefficient calculated using the ExPASy ProtPram tool 
(http://web.expasy.org/protparam/) with respect to the confirmed amino acid sequences.  
2.3 Non-Radioactive Electro-mobility Shift Assays (EMSA) 
Complexes were titrated together between SOX9 protein constructs with a fixed 
concentration of DNA of either a single SOX9 binding site; S9WT, or a double SOX9 
binding site; 36 bp oligonucleotide CC36. The complementary lengths of DNA were 
designed in 36 base pair length (IDT). The DNA-protein binding reactions were 
performed with increasing protein concentrations from 0 to 4.0µM in increments of 
0.5µM titrated with a constant final DNA concentration of 1µM per reaction in a SOX-
DNA binding buffer (10mM NaP, 100mM NaCl, 5mM EDTA, 1mM PMSF, 0.2% NaN3, 
pH 6.0, and 10% glycerol). The final reaction volume was 40µL per sample using the 
SOX9 binding buffer supplemented with 10% glycerol. Complexes were incubated over 
ice for 30-45 minutes and resolved on 10% TBE gels in the cold room at 4°C with an 
added 1kB DNA ladder. The gels were stained with 1X SYBR Green I solution 
(Invitrogen) in a 1:10000 dilution for 40 minutes and visualized with an Alpha Imager 
HP system (Alpha Innotech). Radioactive EMSA’s were performed in a similar manner 
in the nanomolar range, with the exception of P-32 radioactive tagging (Perkin Elmer) of 
the DNA and complex formation performed by Ana Vakiloroayaei. Radioactive detection 
was conducted on a Typhoon 9400 Multi-Format Imager. 
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2.4 Fluorescent-Peptide Electro-mobility Shift Assays (EMSA) 
A shift assay was used to detect the binding of a FITC-peptide 
(GVSIREAVSQVLSGYD) sequence of the SOX9 dimerization domain that was bound 
to a complex with either wildtype or mutant SOX9 proteins to the main oligonucleotide 
CC36 with the double SOX9 binding sites as well as the single SOX9 binding site S9WT. 
Complexes were constructed and incubated over ice for 30 minutes. Protein-DNA 
complexes were titrated together with a fixed final concentration of 1µM DNA of either 
S9WT or CC36 with a fixed concentration of 2µM of SOX9 protein constructs SOX9 
[71/184], SOX9 [101/184], or SOX9 [71/184] A118E, A119E, L142Q, and L145E to 
form 1:2 DNA:SOX9 protein binding reactions. FITC labeled peptide was added to the 
complex with an increasing concentration from 0 to 40µM (0µM, 2µM, 3µM, 6µM, 
8µM, 10µM, 15µM, 20µM, and 40µM). The final reaction volume was 40µL per sample 
using the SOX9 binding buffer supplemented with 10% glycerol. Complexes were 
incubated over ice for 30-45 minutes in the dark to prevent further light exposure and 
resolved on 10% TBE gels with an added 1kb DNA ladder in the cold room at 4°C. The 
gels were visualized using a Carestream 4000 MM Pro Image Station using a multi-
wavelength illumination source with corresponding filters for FITC detection at 495nm 
excitation and 520 nm emission that is characteristic to a FITC tag (Carestream Health). 
Imaging and band intensities were measured using the Carestream Molecular Imaging 
Software.  
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2.5 Circular Dichroism (CD) 
The far UV spectra of His6-SOX9 [71/184] and His6-MBP-SOX9 [101/184] were 
acquired with a Jasco J-810 CD Spectrometer in conjunction with Spectra Manager 
1.54.03 and Spectra Analysis 1.54.04 software (Jasco 815CD) at 20°C using a cell with a 
constant 0.1 cm path length for all measurements. Spectra for SOX9 protein constructs 
alone, either CC36 or S9WT alone, as well as the DNA-protein complex spectras were 
recorded over a wavelength range from 190-300 nm. All spectra samples were acquired 
in a CD binding buffer (10mM NaH2PO4 and 100mM KF). A blank scan of buffer alone 
was also performed to use as a baseline for data processing. All proteins and DNA had a 
final concentration of 30µM in a final volume of 200µL per reaction. There was a total of 
three scans performed for each sample and the data was normalized to mean residue 
ellipticity using the molar protein concentration and number of amino acids for each of 
the individual SOX9 protein constructs. The final CD spectrums for the SOX9 proteins of 
interest were determined by subtracting the free CC36 or S9WT DNA spectra (30µM) 
from the complex (both at 30µM each). Thermal denaturation experiments were also 
conducted for both SOX9 protein alone and in complex with either DNA and monitored 
with the molar ellipticity at 208nm and 222nm at 2°C/minute from 4°C to 90°C. Spectra 
deconvolution was achieved using the online software analysis program CONTINLL 
(Dicroweb) and K2D2 (http://k2d2.ogic.ca).   
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2.6 Fluorescence Anisotropy  
In this study, fluorescence anisotropy was used to determine the binding constants 
and kinetics of the reaction between the single site FITC-S9WT and an increasing 
concentration of either SOX9 [71/184] or SOX9 [101/184]. 100 µL of pure SOX9 
[71/184] or [101/184] protein starting at 400µM was serially diluted to concentrations 
ranging from 200µM down to 1µM with a constant concentration of 1µM of FITC-S9WT 
in a final reaction volume of 40µL per sample using the SOX9 binding buffer. Reactions 
were placed on ice for 30-45 minutes. 10µL reactions were then added to a black 
background 384 well plate in an order of increasing protein concentration and repeated in 
four rows. In addition, four rows each of the buffer alone, protein in buffer alone, and 
DNA in buffer alone were also subjected to polarization tests in two separate readings. 
Foil was placed over the well plate to prevent the exposure of light and placed in a 
centrifuge for 5 minutes at 1000rpm in order to settle the samples to the bottom of each 
well. The plate was read using a Synergy H4 Hybrid reader using polarization intensities 
with an excitation at 495nm and emission at 520nm that is characteristic to a FITC tag. 
Each reading contains two readings for parallel and two readings for perpendicular 
whereby a final polarization is calculated using the Gen5 software corresponding to the 
Synergy apparatus. The final four readings from each of the rows were averaged for a 
final polarization value for each concentration and then repeated three times for a final 
average.   
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2.7 1H-15N HSQC Nuclear Magnetic Resonance (NMR) Spectroscopy of SOX9 
[101/184] 
15N-isotopically labeled SOX9 [101/184] complexed with the single site S9WT 
DNA was produced by growing 3L of E.coli BL21:DE3 in M9 minimal media 
supplemented with 1 g/L [15N] ammonium chloride as a means of being the sole nitrogen 
source. Singly labeled proteins were generated for 1H-15N heteronuclear single quantum 
coherence (HSQC) investigations. Previous growth and purification protocols were 
implemented and following gel filtration, pure protein was concentrated to 0.1-0.15M 
using a Pall Corporation MWCO 3000 filter overnight at 4°C and supplemented with 
10% D2O. A 1:1 concentration of DNA:SOX9 were complexed together and left over ice 
for 30-45 minutes and HSQC spectras were acquired on a 700 MHz Bruker Ascend NMR 
spectrometer.  
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________________________________________________________________________ 
CHAPTER III 
RESULTS 
________________________________________________________________________ 
3.1 Stability of SOX9 Constructs  
The expression of SOX9 [71/184], detagged-SOX9 [101/184], SOX9 [71/184] 
A118E, SOX9 [71/184] A119E, SOX9 [71/184] L142Q, and SOX9 [71/184] A145E  
(Figure 10) were all confirmed with their correct molecular weights by SDS-PAGE. 
SOX9 is sensitive to temperature, pH, and salt conditions. Detagged-SOX9 [101/184] 
expression was more limited in 15N media than LB, which required an increase in 
culturing with lower and longer post-induction temperatures in order to compensate 
for a decrease in expression. All six expressed proteins remained stable in a sodium 
phosphate buffer pH 6-8 with salt concentrations between 100-500mM. Aggregation 
became an issue for the constructs over 100mM in concentration as precipitate formed 
and facilitated a loss of more than 50% of protein by the final stages of purification and 
storage. When kept on ice, loss of protein due to degradation and aggregation were 
greatly reduced. In addition, protease inhibitors were added to elutions and final 
buffers to reduce serine proteases as well as buffers were reduced to pH 6 to reduce 
tryptophan proteases. Both constructs generated ~90% of recombinant proteins were 
produced as insoluble aggregates. This was resolved by solubilizing the inclusion 
bodies with 6 M urea prior to conducting affinity purifications. The shelf life for the 
SOX9 proteins were approximately 5-10 days however with the use of 30% glycerol and 
storage in the -20°C freezer, the shelf life could be extended for a couple of months.
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Figure 10: Confirmation of SOX9 constructs SOX9 [71/184], detagged-SOX9 [101/184], SOX9 [71/184] A118E, and SOX9 
[71/184] A119E with their correct molecular weights at 15kDa, 10kDa, 15kDa, and 15kDa respectively. Visualized on a 12% SDS gel 
using a protein ladder (Biorad Precision Plus Protein™ Dual Color Standards) and visualized with Fast SeeBand Single Step Protein 
staining solution (FroggaBio) on the Alpha Imager HP system (Alpha Innotech). Arrows indicate the band with the correct molecular 
weight.   
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3.2 DNA Binding of Wildtype SOX9 [71/184] and [101/184] and SOX9 Mutants 
Non-radioactive electrophoretic mobility shifts assays (EMSAs) of S9WT 
complexed with SOX9 [71/184] (Figure 11A) or monomeric SOX9 [101/184] (Figure 
11B) with S9WT were used to visualize and confirm that SOX9 does bind to DNA and 
demonstrating that the minimal domain required for binding is the HMG domain. This is 
demonstrated by the binding between SOX9 [101/184] and S9WT or CC36. CC36 
complexed with either SOX9 [71/184] (Figure 12A) or SOX9 [101/184] (Figure 12B) 
demonstrates the role of cooperativity when the dimerization domain is present. With just 
the HMG present SOX9 [101/184] initially binds to one site until the concentration of 
protein is about 2µM at which point it binds to and saturates both sites on CC36. While 
SOX9 [71/184] containing both the dimerization domain and the HMG bound to both 
sites almost simultaneously, revealing that even at low concentrations immediate patterns 
of occupying both sites on the DNA. When compared to SOX9 [71/184] HMG domain 
mutants A118E and A119E the A118E mutant (Figure 15A) was still able to demonstrate 
dimerization with a similar pattern the wildtype SOX9 [71/184]. However A119E 
(Figure 15B) demonstrated a loss of dimerization. Although, both mutant constructs 
retained the ability to bind to DNA. Similarly, the SOX9 [71/184] L142Q mutant bound 
to CC36 (Figure 16A) demonstrates a loss of dimerization comparable to A119E. 
Likewise, L145E mutant (Figure 16B) maintains its ability to dimerize and exhibit 
cooperativity much like the A118E mutant.  
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Figure 11: Non-radioactive electrophoretic mobility shift assays of wildtype SOX9 constructs 
with the single-site S9WT DNA. (A) EMSA shift of wildtype SOX9 [71/184] and (B) of wildtype 
SOX9 [101/184] with an increasing concentration (0µM, 0.5µM, 1µM, 1.5µM, 2µM, 2.5µM, 
3µM, 3.5µM, 4µM) in complex with 1µM of S9WT. Complex was resolved on a 10% TBE gel 
and stained with 1:10000 dilution of SYBR Green. The final lane contains a 1kb DNA ladder.    
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Figure 12: Non-radioactive electrophoretic mobility shift assays of wildtype SOX9 constructs 
with the double-site 36bp CC36 DNA. (A) EMSA shift of wildtype SOX9 [71/184] demonstrating 
cooperativity and (B) of wildtype SOX9 [101/184] occupying the one of two sites on the DNA 
first with an increasing concentration (0µM, 0.5µM, 1µM, 1.5µM, 2µM, 2.5µM, 3µM, 3.5µM, 
4µM) in complex with 1µM of CC36. Complex was resolved on a 10% TBE gel and stained with 
1:10000 dilution of SYBR Green. The final lane contains a 1kb DNA ladder.  
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Radioactive EMSAs provided a means to determine the Kd for SOX9 [71/184] 
with S9WT (Figure 13A), SOX9 [101/184] with S9WT (Figure 13B), SOX9 [71/184] 
with CC36 (Figure 13C), and SOX9 [101/184] with CC36 (Figure 13D). Binding shifts 
were demonstrated under 20nM of SOX9 [101/184] with 9nM of S9WT while other 
complexes demonstrated visible shifts under 50nM. The plotted percent of SOX9 protein 
unbound to either DNA (Figure 13E) revealed a sigmoidal binding curve. However, the 
algorithmic calculations using Prism (GraphPad Software) of the Kd were approximately 
35nM for SOX9 [101/184] with S9WT and approximately 100nM for the other 
constructs. SOX9 [71/184] with S9WT bound to 83% completion and as a result will 
need to be repeated.   
3.3 The Surface on the Sox Group E HMG Domain also Participates in Binding with 
the Dimerization Domain 
FITC-peptide of the dimerization domain sequence (α0) of SOX9 enabled 
florescence electrophoretic mobility shift assays to be conducted using a 2:1 preformed 
complex of SOX9 [71/184] or SOX9 [101/184] with DNA. An increase in the intensity 
was present with an increase in peptide concentration for SOX9 [71/184] bound to S9WT 
(Figure 14A) and when bound to CC36 (Figure 14C). A similar intensity increase was 
detected when SOX9 [101/184] was bound to S9WT (Figure 14B) or CC36 (Figure 
14D). Peptide titrated with DNA alone demonstrated no binding with any construct. 
However, the mutants SOX9 [71/184] A118E and A119E demonstrate very different 
affinities for the FITC-peptide. SOX9 [71/184] A118E bound to CC36 (Figure 15C) 
reveals a similar increase in intensity in FITC-peptide as the concentration increases, as 
did the wildtype SOX9 constructs. However, SOX9 [71/184] A119E bound to CC36 
(Figure 15D) reveals no detection of the peptide binding to the preformed complex. The 
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Figure 13: Radioactive electrophoretic mobility shift assays of S9WT with (A) SOX9 [71/184] 
and (B) SOX9 [101/184] and using CC36 with (C) SOX9 [71/184] and (D) SOX9 [101/184] 
with an increasing concentration of SOX9 proteins (0nM, 10nM, 20nM, 30nM, 40nM, 50nM, 
100nM, 150nM, 200mM, and 250nM). (E) Sigmodial plot of the unbound percentages of the 
SOX9 proteins bound to DNA. 
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Figure 14: FITC-peptide of SOX9 dimerization domain EMSA with 2µM of wildtype (A) SOX9 
[71/184] with 1µM S9WT; (B) SOX9 [101/184] with 1µM S9WT; (C) SOX9[71/184] with 1µM 
CC36; (D) SOX9 [101/184] with 1µM CC36. FITC-peptide in an increasing concentration (2µM, 
3µM, 4µM, 6µM, 8µM, 10µM, 15µM, 20µM, 40µM, and 5µM peptide with 1µM DNA alone). 
Complex was resolved on a 10% TBE gel and detected with UV-light on a CareStream Imager 
(Carestream Health). There was no detection of FITC-peptide binding to DNA alone.          
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Figure 15: Non-radioactive electrophoretic mobility shift assays of mutant SOX9 constructs with 
the double-site 36bp CC36 DNA. (A) EMSA shift of mutant SOX9 [71/184] A118E and (B) of 
mutant SOX9 [71/184] A119E with an increasing concentration (0µM, 0.5µM, 1µM, 1.5µM, 
2µM, 2.5µM, 3µM, 3.5µM, 4µM) in complex with 1µM of CC36. Complex was resolved on a 
10% TBE gel and stained with 1:10000 dilution of SYBR Green. The final lane contains a 1kb 
DNA ladder. (C) FITC-peptide of SOX9 dimerization domain EMSA with 2µM SOX9 [71/184] 
A118E with 1µM of CC36 DNA (D) or 2µM SOX9 [71/184] A119E and 1µM CC36 with 1µM 
of CC36 DNA. Increasing concentration of FITC-peptide (2µM, 3µM, 4µM, 6µM, 8µM, 10µM, 
15µM, 20µM, 40µM, and 5µM peptide with 1µM CC36 DNA alone). Complex was resolved on a 
10% TBE gel and detected with UV-light on a CareStream Imager (Carestream Health). There 
was no binding detection of peptide with the mutant SOX9 [71/184] A119E or detection of 
FITC-peptide binding to DNA alone.
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Figure 16: Non-radioactive electrophoretic mobility shift assays of mutant SOX9 constructs with 
the double-site 36bp CC36 DNA. (A) EMSA shift of mutant SOX9 [71/184] L142Q and (B) of 
mutant SOX9 [71/184] L145E with an increasing concentration (0µM, 0.5µM, 1µM, 1.5µM, 
2µM, 2.5µM, 3µM, 3.5µM, 4µM) in complex with 1µM of CC36. Complex was resolved on a 
10% TBE gel and stained with 1:10000 dilution of SYBR Green. The final lane contains a 1kb 
DNA ladder. (C) FITC-peptide of SOX9 dimerization domain EMSA with 2µM SOX9 [71/184] 
L142Q with 1µM of CC36 DNA (D) or 2µM SOX9 [71/184] L145E and 1µM CC36 with 1µM of 
CC36 DNA. Increasing concentration of FITC-peptide (2µM, 3µM, 4µM, 6µM, 8µM, 10µM, 
15µM, 20µM, 40µM, and 5µM peptide with 1µM CC36 DNA alone). Complex was resolved on a 
10% TBE gel and detected with UV-light on a CareStream Imager (Carestream Health). There 
was no binding detection of peptide with the mutant SOX9 [71/184] L142Q or detection of FITC-
peptide binding to DNA alone.
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Kd and Hill coefficient values associated with the peptide binding to any of the SOX9-
DNA complexes (Table 2) are fairly similar; ~8-9 Kd with a value of 3 for the Hill 
coefficient, and conform to a similar sigmoidal curve when normalized (Figure 17). This 
is with the exception of SOX9 [71/184] A119E whereby there were no band intensities to 
measure. Similarly, the SOX9 [71/184] L142Q mutant bound to CC36 (Figure 16C) was 
unable to bind with the peptide and no bands were detected. Unlike, mutant L145E 
(Figure 16D) that retained an affinity for the peptide of the dimerization domain and 
exhibited an increase in fluorescence intensities as the peptide concentration increased.  
3.4 Stability or DNA Binding Affinity of the Wildtype SOX9-DNA Complex is Not 
Enhanced by the Dimerization Domain  
The qualitative circular dichroism spectroscopy scans for SOX9 [71/184] 
demonstrated a shift in the alpha helix profile when bound to S9WT and CC36 compared 
to the protein alone as demonstrated by the raw data confirming the presence of the 
complex (Figure 18A & 18B) and the actual shifts when the DNA was subtracted  
(Figure 18C). Similarly, a shift in the profile was present in the scans for SOX9 
[101/184] bound to S9WT and CC36. This is confirmed by the raw data complex formed 
between the SOX9 protein and either S9WT or CC36 (Figure 19A & 19B) as well as 
when DNA is subtracted from the profiles (Figure 19C). Spectra deconvolution was 
achieved using the online software analysis program CONTINLL (Dicroweb) and K2D2 
(http://k2d2.ogic.ca) to determine 91% alpha helix protein structure for SOX9 [71/184] 
alone and when complexed to CC36 and 88% when complexed to S9WT. Similarly, 
SOX9 [101/184] alone or when bound to either CC36 or S9WT had a 94% alpha helix 
structure with a 0.01% likelihood of a beta sheet present. The secondary structure of both 
SOX9 protein constructs alone were also confirmed using the secondary structure 
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Figure 17: Normalized intensities for His6-SOX9 wildtype and mutant constructs against 
FITC-peptide concentration (µM) of the SOX9 dimerization domain sequence.   
SOX9 
[71/184] + 
CC36 
SOX9 
[101/184] + 
CC36 
SOX9 [71/184]  
A118E +   
CC36 
SOX9 
[71/184] + 
S9WT 
SOX9 
[101/184] + 
S9WT 
 Kd  8.35±0.27 7.95±0.21 6.90±2.16 10.45±0.51 7.02±0.21 
Hill 3.170 2.900 2.160 3.260 2.830 
Table 2: Kd and Hill values for His6-SOX9 wildtype and mutant constructs with S9WT or CC36 
DNA     
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Figure 18: Raw data of free (blue) and bound (green) His6-SOX9 [71/184] at 20°C with (A) S9WT DNA (pink) (B) CC36 
DNA (pink). CD spectra of the protein and DNA region (200-300nm). (C) Normalized CD spectra of His6-SOX9 
[71/184] with either S9WT (purple) or CC36 (orange) compared to His6-SOX9 [71/184] protein alone (blue) demonstrates 
and altered alpha helix profile when bound to DNA.       
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Figure 19: Raw data of free (blue) and bound (green) His6-SOX9 [101/184] at 20°C with (A) S9WT DNA (pink) (B) 
CC36 DNA (pink). CD spectra of the protein and DNA region (200-300nm). (C) Normalized CD spectra of His6-SOX9 
[101/184] with either S9WT (purple) or CC36 (orange) compared to His6-SOX9 [101/184] protein alone (blue) 
demonstrates and altered alpha helix profile when bound to DNA.       
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prediction program PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/) (Figure 20). As 
forecasted, the program predicted that SOX9 [71/184] contains one alpha helix within the 
dimerization domain and three alpha helices within the HMG domain while SOX9 
[101/184] only contains the three alpha helices within the HMG domain. 
The dimeric SOX9 [71/184] and monomeric SOX9 [101/184] proteins revealed a 
thermal denaturation midpoint (Tm) at 45 ̊ C for either protein constructs alone. This 
indicates that the HMG domain remains largely unfolded at room temperature. Given that 
the melting temperatures of both are the same, it suggests that the dimerization domain 
does not play a significant role in the stabilization of the HMG domain. When the studies 
were performed with the proteins in complex with the 36 bp DNA duplex, CC36; a 
palindrome containing two inverted CACAAAG binding sites, as well as a single site 
DNA; S9WT the Tm increased respectively for SOX9 [71/184] (Figure 21A) when 
complexed with S9WT to 68°C and CC36 to 69°C. Likewise, the values for SOX9 
[101/184] (Figure 21B) increased when complexed to S9WT to 65°C and with CC36 to 
65°C. Furthermore, melting of the DNA alone was approximately 60°C. This proposes 
that stabilization of the DNA-bound protein complex is not hindered or affected by any 
protein-protein contacts as a result of the dimerization region being present.  
The reaction between the single site FITC-S9WT and an increasing concentration 
of either SOX9 [71/184] or SOX9 [101/184] enabled a change in rotational time of the 
molecules such that if the SOX9 protein bound to the FITC-DNA it would slow down the 
rotation of the DNA and enable an increase in detection of polarization. The fluorophore 
bound to S9WT demonstrated a difference in polarization between the unbound and 
bound state. SOX9 [71/184] bound to FITC-S9WT demonstrated a smaller spike in 
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Figure 20: Secondary structure prediction of SOX9 constructs. The alpha 
helices prediction of (A) SOX9 [71/184] (B) SOX9 [101/184] using prediction 
program PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/).   
A 
B 
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Figure 21: Melting of His6-SOX9 wild type constructs free and bound to S9WT or CC36. (A) His6-SOX9 [71/184] alone (blue) 
melted at 45°C and bound to S9WT (purple) melted at 68°C or bound to CC36 (green) melted at 69°C. (B) His6-SOX9 
[101/184] alone (blue) melted at 45°C and bound to S9WT (purple) melted at 65°C or bound to CC36 (green) melted at 65°C. 
Melting of both His6-SOX9 wild type constructs at very similar temperatures is indicative that the thermal stability is not altered 
with the addition of the dimerization domain in the His6-SOX9 [71/184] construct.        
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polarization at 10nM, 20nM, 50nM, and a larger spike at 100nM. This is similar to 
SOX9 [101/184] bound to FITC-S9WT whereby there was an initial spike at 10nM, 
15nM, 40nM, and a greater spike at 100nM. However, the data was not consistent or 
accurate enough to determine a saturation curve and Kd values from.  
3.5 1H-15N-13C HSQC Nuclear Magnetic Resonance (NMR) Spectroscopy of His6-
SOX9 [101/184]  
HSQC data collected from the 700 MHz Bruker magnet for SOX9 [101/184] 
complexed with the single site S9WT required a program known as NMR Analysis in 
order to asses the peak data. As a result, approximately 56 of the 83 peaks were present. 
An imino test was performed to confirm the presence of DNA with 10 defined peaks as 
predicted. However, protein degradation hindered a complete spectrum from being 
constructed and assigned. 
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________________________________________________________________________ 
CHAPTER IV 
DISCUSSION 
________________________________________________________________________ 
4.1 The Binding Mechanism of SOX9 
Cellular processes such as chondrogenesis and sex determination are regulated by 
the structural confirmations and complex formations of SOX9. Oligomer formation is one 
of the unique mechanisms employed by SOX9 proteins that differentiate its mode of 
specificity and subsequent function. Binding of both SOX9 [71/184] and SOX9 
[101/184] with S9WT or CC36 provided an indication that the HMG domain of SOX9 is 
the only platform required to form a SOX9-DNA complex and retain the affinity for 
DNA. Using radioactive and non-radioactive electrophoretic mobility shift assays with 
wildtype SOX9 [71/184] and SOX9 [101/184] it is established that the presence of an 
intact dimerization domain enables the binding to DNA CC36 at both sites directly and 
subsequently demonstrating cooperative dimerization.  This suggests that a stable 
complex is formed in the presence of an intact dimerization domain.  More so, the 
reciprocal interaction of one dimerization region with another HMG domain on a tandem 
promoter is a fundamental attribute of a novel binding mechanism. 
Furthermore, disruption of the two conserved alanine residues in the Sox E 
Family of proteins demonstrated that when substituted, the first of two Alanines in 
the HMG domain at A118E had no impact on the ability of the SOX9 [71/184] 
mutant to form a stable confirmation of binding to both sites on CC36 in a similar 
cooperative manner as the wildtype SOX9 [71/184]. SOX9 [71/184] A119E loss 
the ability to dimerize and cooperatively bind to the double-sited oligonucleotide CC36.
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In addition, there is a loss of affinity between the mutant HMG domain and the 
dimerization domain. This suggests that the second Alanine residue plays a more critical 
role in exposing a greater binding surface related with the complex formed between two 
identical SOX9 [71/184] on a double site DNA. Both mutants still retain a surface that 
permits the HMG domain to bind with DNA. With respect to the two Leucines unique to 
the Sox E Group of proteins, the mutants L142Q and L145E, the SOX9 [71/184] L142Q 
mutant is present within the second alpha helix of the three that make up the HMG 
domain. Upon mutating the second alpha helix (α2) with a single amino acid substitution 
SOX9 [71/184] L142Q the hydrophilic replacement reduces surface exposure losing the 
ability to form a dimer in a cooperative manner and affinity to bind to the dimerization 
domain. Unlike the SOX9 [71/184] L145E mutant that is present in the two amino acid 
linker region between the second and third alpha helices of the HMG domain, L145E 
does not affect the proteins ability to bind cooperatively or bind to the peptide of the 
dimerization domain. This suggests that the third alpha helix (α3) of the HMG domain 
may have a less significant role and potentially not dock onto the alpha helix of the 
dimerization domain (α0) unlike the first and second alpha helices that dock directly onto 
α0 to form a stable complex.  
A118 and L145 of the HMG domain are oriented away from the dimerization 
domain-docking groove such that the A118E or L145E substitution does not interfere 
with the binding surface. Replacing either Alanine or Leucine with a Glutamic acid 
would only propel the longer hydrophilic side chain to orient further out into the external 
environment as opposed to burying itself into the inner hydrophobic core.
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Although A119 and L142 are also on the surface, its stable conformational state 
is aligned toward the docking groove. A mutation at A119E or L142Q could 
contribute a negative charge that generates steric hindrance between the HMG and 
dimerization domain surfaces that would otherwise make contact (Figure 22).
Previous mutant studies conducted by Shokofeh Shahangian demonstrated 
that particular amino acids I73, A76, V77, V80, L81, and Y84 were critical for 
mediating dimerization which supports the data that the dimerization domain 
folds into an amphipathic helix post its commitment to binding (Bernard et al., 2003).  
This can also contribute to the notion that the thermal stability of the SOX9-DNA 
complex is not affected by the presence of the dimerization domain. When bound 
to CC36, SOX9 [71/184] with an intact dimerization domain exhibits cooperativity. 
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Figure 22: Point mutations via Pymol to the HMG domain of SOX9. (A) Representation of single point mutations at A118E 
and A119E in the first alpha helix of the HMG domain. A119E demonstrates greater steric hindrance than A118E (B) Single 
point mutations at L142Q and L145E in the second alpha helix of the HMG domain. L142Q demonstrates greater steric 
hindrance than L145E. 
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4.2 The Effect of the Dimerization Domain 
SOX9 [71/184] complexed to S9WT or CC36 shows that the peptide can interfere 
with a preformed complex. The hydrophobic surface of the peptide assists in stabilizing 
the complex. The complex between SOX9 [101/184] with S9WT or CC36 demonstrates 
how the peptide i.e., the dimerization domain, can specifically recognize the HMG 
domain-DNA interface to generate another plane of structural and functional specificity 
(Figure 23. With the dimerization in trans, the HMG domain is the platform the peptide 
requires for binding. Amongst the Sox E family of proteins, the amphipathic helix of the 
dimerization domain can bind across the hydrophobic cleft of the HMG domain.  The 
dimerization domain does not affect DNA binding given that electrophoretic mobility 
shifts are still detected even in the absence of the dimerization domain with SOX9 
[101/184]. Given that there was no florescent signal of the peptide with DNA alone it 
suggests that the dimerization domain does not posses an affinity for either the single or 
double site DNA.
Given that A118, A119, L142, and L145 are largely exposed surfaces and 
hydrophobic as per the SOX9-DNA crystal structure, mutations to the HMG domain that 
substitute the two conserved alanines or the unique Leucines with a hydrophilic 
amino acid native to SRY or SOX18 does not hinder the ability of SOX9 to bind 
to DNA as demonstrated by the shifts stained with SYBR Green. Fluorescence 
shifts with the dimerization peptide revealed no indication of the peptide binding to 
the SOX9 A119E-DNA complex as well as the L142Q-DNA complex. This is 
consistent with the loss of dimerization demonstrated by the A119E and L142Q shift. 
Although the HMG retains the ability to bind to DNA and form a complex, the initial 
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Figure 23: A docking simulation of how the alpha helix (α0) of the dimerization 
domain of SOX9 would dock onto the first and second alpha helix (α1, α2) of its 
own HMG domain. The surface exposure of specific amino acids are also revealed 
including the di-alanine sites at A118 and A119 and two leucines at L142 and L145 
that are unique to the Sox E Group of proteins (Courtesy of Dr. Logan Donaldson).  
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exposed surface that becomes mutated prevents the peptide from interfering and binding 
with the preformed complex. A118E and L145E maintain their ability to dimerize 
and as a result the peptide can obstruct and bind the preformed complex enabling 
detection of the peptide.  
4.3 Characterization of the Dimerization and HMG Domain of SOX9 [71/184] 
Peptide disassociation constants SOX9 [71/184], SOX9 [101/184], and SOX9 
mutant A118E were calculated using pro Fit by Quantum Soft with the assistance of Dr. 
Logan Donaldson. The binding of the peptide on the complex of SOX9 [71/184] 
containing the dimerization domain with CC36 DNA employs a more sigmoidal-type 
progression unlike the SOX [101/184]-CC36 complex that demonstrates a more linear 
binding slope. This exact pattern is visible with the P-32 radioactive EMSAs between 
SOX9 [71/184] and SOX9 [101/184] complexed with CC36. As Coustry and 
colleagues demonstrated, the slower more sigmoidal progression of SOX9 [71/184] with 
a functional dimerization domain is indicative that binding of SOX9 to its recognition 
sites of the DNA is a more cooperative process (Coustry et al., 2010). This provides 
insight into the role of the dimerization domain in chromatin remodeling to initiate 
transcription and how the dimerization domain may elicit a stronger activation of the 
promoter or enhancer by running at a higher efficiency and having a greater output of 
transcripts (Coustry et al., 2010). ChiP assays have previously confirmed that an intact 
dimerization domain of SOX9 is essential for chromatin remodeling via Mnase digestion 
assays in order to activate transcription of the Col2a1 enhancer containing a double-site 
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consensus and non-consensus sequence. Despite the non-functional dimerization domain 
deletion mutant interacting with the chromatin, in specific instances, the SOX9 mutant 
was unable to activate transcription like the intact dimerization domain wildtype SOX9 
(Coustry et al., 2010).  
Without the presence of a functional dimerization domain such as the SOX9 
mutant or in the case of this study SOX9 [101/184], these particular constructs are unable 
efficiently disrupt the chromatin necessary for transcription once confronted by the 
nucleosomes on the template (Coustry et al., 2010). It is possible that the dimerization 
domain upstream of HMG domain on SOX9 recruits co-factors that link to RNA 
polymerase II and assist in unraveling the chromatin for the HMG domain to dock onto 
the DNA and initiate transcription. However, in the absence of the domain, interactions 
with chromatin are maintained and limited transcription of some reporters containing 
promoters that are targets of SOX9 can still be initiated (Coustry et al., 2010). The 
binding affinity of SOX9 [71/184], SOX9 [101/184], and SOX9 mutant A118E with 
either DNA did not differ in the order of magnitude for the Kd or the Hill coefficient for 
peptide binding with the respective plotting of the normalized intensities.
The positive cooperativity was approximately 3 for all constructs with the 
exception of SOX9 [71/184] A119E. This compares to the strong cooperativity between 
oxygen and hemoglobin (Stefan and Le Novère, 2013). Furthermore, given that the 
peptide was unable to bind to the A119E mutant, a disassociation constant was unable to 
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be calculated. The Kd for the peptide binding to the various SOX9-DNA preformed 
complexes were all within the same boundaries of 10μM. The A118E mutant has a 
greater negative hydrophilic side-chain oriented away from the hydrophobic core that 
could alter the binding surface for the peptide to bind to the preformed SOX9-DNA 
complex. Likewise, the lack of binding of the dimerization domain peptide to the 
mutated HMG domain in SOX9 [71/184] A119E suggests that the original Alanine at 
position 119 of the HMG domain is an essential residue of the HMG binding pocket and 
plays a significant role in creating an affinity interface between the dimerization domain 
and the HMG domain (Figure 23). The peptide did not have any platform within the 
HMG domain of the A119E mutant to bind to the protein. Steric hindrance could alter 
the reactivity pattern of the SOX9-DNA whereby the HMG domain binding pocket 
becomes less surface-exposed and prevent a docking site for the peptide. Both SOX9 
[71/184] and SOX9 [101/184] enable peptide binding providing that SOX9 [71/184] 
with the intact dimerization domain and HMG domain can create a trans-
dimerization model that enables the peptide to intervene with the pre-formed complex 
while SOX9 [101/184] containing just the HMG domain provides a surface 
exposed groove for the peptide to dock onto.    
The HMG domain of SOX family is structured and maintains conserved 
folding. Conserved amino acids within the Sox E group family include Q117, A118, 
A119, T138, and L142 (Schlierf et al., 2002). The structure of the HMG domain consists 
of three alpha helices that are oriented in an L-shaped arrangement.  The mutation 
study of A117V of SOX10 that is equivalent to A118 of SOX9, disrupts cooperative 
binding (Schlierf et al., 2002). This study is indicative of an interaction between the
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helices of the HMG domain and the dimerization region potentially due to the 
conservation of amino acids (Goji et al., 1998; Schlierf et al., 2002). The 
mutational study of A119E demonstrated a monomeric band shift with SOX 
[71/184] on DNA as opposed to the wildtype band shifts. In addition, the HMG is 
defined as having two wings; the major wing consisting of alpha helices 1 and 2 and 
the minor wing defined as helix 3 (Cary et al., 2001). Both wings are thought to 
work independent of each other and although both wings bind to DNA it is the major 
wing that is flexible enough enabling it to have the potential to be the working wing 
associated with protein interactions (Cary et al., 2001). Likewise, SOX9 [71/184] 
may have similar interaction fate between helices 1 and 2 as SOX10.  
This study puts forth that stable binding of the peptide in the ternary complex 
involves peptide-protein contacts with the HMG domain but not the dimerization domain 
of the SOX9 protein. Such binding does not involve peptide-DNA contacts given that 
there is no detection of peptide with DNA alone (Chasman et al., 1999). Binding of the 
dimerization domain peptide can stimulate cooperative trans-dimerization with SOX9 
[101/184] whereby the complementary interaction of one dimerization region with 
another HMG domain on a tandem promoter is a fundamental attribute of the binding 
mechanism. This could be the model required for processes like chondrogenesis 
providing a point of control for tissue-specific regulation of gene expression by a SOX 
transcription factor. The dimerization domain may confer additional 
stimulatory effects on transcription by interfering with the transactivation of 
enhancers such as Col9a2 and Col11a2 involved in chondrocyte 
differentiation (Bernard et al., 2003).  
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4.4 Predicted SOX9 [71/184] Model and Validation  
The long linker located between the C-terminus of the dimerization domain and N-
terminus of the HMG domain facilitates the orientation between both domains. This is 
suggestive of an alternative novel trans-dimerization model (Figure 24) of SOX9 
[71/184] homodimers whereby the dimerization domain of one protein docks onto the 
HMG domain of the second protein. The docking of the hydrophobic face of the 
dimerization domain helix to the HMG domain is optimal because it provides a favorable 
position for the hydrophobic amino acids to orient themselves to preferably minimize 
surface exposure. A119E mutant is known to contribute to Campomelic Dysplasia 
and although it retains the ability to bind to DNA, it does not maintain cooperativity in 
parallel to the wildtype SOX9 [71/184]. This is suggestive that the dimerization 
domain helix may also shield the residues exclusive to the Sox E group of proteins. 
This model could be applied to SOX10 such that there is an increase in affinity for 
the non-consensus binding site after the binding of the first SOX protein to the 
consensus sequence (Bernard et al., 2003; Sock, 2003). Non-consensus binding of 
SOX10 is initiated by the binding of a single SOX10 docking on the consensus binding 
site which triggers the folding of the dimerization such that it will then bind to the HMG 
domain of a second identical SOX10 protein (Schlierf et al., 2002). The second SOX 
protein would have a higher affinity for binding to a non-consensus sequence that will 
be followed by the folding of the dimerization domain of the second protein and binding 
to the HMG domain of the first protein to establish a stable complex in trans 
increasing the stability of the proteins as a complex (Schlierf et al., 2002). The trans-
dimerization model is only applicable when the two binding sites are not equal. 
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Figure 24: The trans-dimerization model. SOX9 [71/184] is represented by its HMG domain (green) and 
dimerization domain (pink) attached by a linker region with a double site (dark grey) DNA (light grey). 
The model infers that the HMG domain of the first SOX9 [71/184] binds to the consensus DNA site and 
induces a bend in the DNA. The HMG domain of a second identical SOX9 [71/184] docks onto the 
dimerization domain of the first SOX9 [71/184] protein which is followed by the HMG domain of the 
second SOX9 [71/184] binding to the second non-consensus site on the DNA. This enables the 
dimerization domain of the second SOX9 [71/184] to bind to the HMG domain of the first SOX9 [71/184].       
1 2 
3 4 
5 6 
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For example, tandemly inverted promoters that demonstrate unequal binding sites due to 
a difference in affinity similar to the Po promoter binding to SOX10 (Peirano and 
Wegner, 2000). Furthermore, the difference in sequences of SOX9 binding sites for 
example between Col11a2 and Col2a1 can affect concentration-dependent binding and as 
a result influence binding affinities between DNA, SOX9, and the recruitment of multiple 
transcription factors that SOX9 supports and in turn supports SOX9 affecting 
the accessibility of chromatin sites (Coustry et al., 2010). 
 The dimerization domain helix of SOX9 has a hydrophobic face. Those 
hydrophobic amino acids are oriented such that surface exposure is minimized. As per the 
structural model, the positioning of the dimerization domain over the HMG domain 
will decrease the surface exposure as well as mask the hydrophobic residues (Figure 
25A & 25B). Upon binding SOX9 will bind to the minor groove of DNA and cause it 
to bend 108° toward the major groove. The bending of DNA may contribute to the 
regulatory functions of SOX9 (Figure 25C). 
4.5 The Importance of Trans Binding of SOX proteins to DNA  
The trans-dimerization hypothesis emerged from a study that switched helices α 
1/α 2/α 3 from the HMG domain of SOX10 with those from SOX11, a Group C family 
member that does not dimerize (Schlierf et al., 2002). From this study, it appeared the α 
1/α 2 contained an important determinant of dimerization as they could not be swapped 
with their corresponding helices from SOX11. The study suggests that the dimerization 
domain and the Sox10-specific HMG domain have to be present on the same Sox10 
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Figure 25: (A, B) A molecular model rotated at two angles of a dimerized SOX9 protein 
complexed with a double-site DNA. The HMG bound to DNA bends the DNA such that the 
dimerization domain of one SOX9 protein binds to the HMG domain of a second identical 
protein. The HMG domain of the second identical SOX9 is also bound to a second site on DNA. 
The two sites on the DNA are palindromic sequences that are characteristic of the high affinity 
sites on DNA for the SOX family of proteins. (C) The model demonstrates how the HMG domain 
of SOX9 is capable of bending DNA at a single site (PDB: 4EUW). (Courtesy of Dr. Logan 
Donaldson). 
A 
B 
C 
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molecule for intramolecular function of both domains with the potential for two 
HMG domains and two dimerization domains to interact with each other in a 
trans-binding manner between two Sox10 molecules (Schlierf et al., 2002). The 
mixture of binding complexes could be a direct result of the difference in 
endogenous sources of Sox9 under different physiological conditions such as 
incubation time. Binding to DNA differs between cis and trans depending on the 
incubation period (Lippard and Hoeschele, 1979). Additionally, orientation of 
the transcription factor can contribute to complex formation. Both the cis and 
trans complex formation can contribute to marked changes in the expression of 
Sox9 and isoforms within tissues over the course of development in the 
embryo. Each complex structure can play a role in the response patterns and trans-
activating specific response elements that may have a distinct function or 
distinct gene products associated with its activation and subsequent 
function.  
4.6 The Clinical Affect of Improper or Lack of SOX9-DNA Complex Formation  
The lack of binding of SOX9 to DNA or improper formation of the protein-DNA 
complex leads to drastic affects on early embryonic development in terms of both sex 
determination and cartilage formation. During testis development SOX9 increases in 
expression in order to maintain a positive feedback loop to influence to activation of co-
factors including growth factors as well as many other genes. In addition, SOX9 
72
auto-regulates itself to maintain a threshold expression level to inhibit factors such as R-
spondin-1 that is necessary to inhibit ovary formation. Without the binding of SOX9 to a 
sex-determination specific promoter or enhancer, the downstream cascade of events 
necessary to maintain the male sex determination cannot be activated and the propensity 
for a female-sex reversal phenotype becomes highly probable.   
Improper or the lack of SOX9-DNA complex formation can lead 
to defects in chondrogenesis. Specifically SOX9 is a regulator of the type II 
collagen gene. A mutation to the dimerization domain deeming it nonfunctional can 
reduce or inhibit the activation of chondrocyte-specific reporters that are vital 
to initiate the process of chondrogenesis during early embryonic development. 
Misexpression of SOX9 results in ectopic cartilage formation of the limbs as well as 
alter the aggregation properties of limb mesenchymal cells such that cell condensation 
is reduced or lost ultimately affecting early skeletogenesis (Healy et al., 1999). 
Additionally, SOX9 plays a critical role in the cartilage differentiation programme 
in dermomyotomal cells that generate axial musculature and dermis (Healy et al., 
1999). Such misimpression of SOX9 can inhibit the process of such cells committing to 
its normal cell fate by affecting the regulation of Pax1, a marker for ventral 
development downstream (Healy et al., 1999).  
Alternatively, formation of the SOX9-DNA complex at an unsuitable time can 
have negative implications on development. SOX9 is a negative regulator of bone 
marrow formation, cartilage vascularization and endochondral ossification (Hattori et al., 
2010). Complex formation can affect the ability of proliferating chondrocytes to further
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differentiate into hypertrophic chondrocytes and eventually calcified cartilage (Akiyama 
et al., 2002). Its down regulation may be necessary to initiate cartilage-to-bone 
transition in the growth plate (Hattori et al., 2010). Under the control of the BAC-
Col10a1 promoter, transgenic newborn mice demonstrate vascular invasion into 
hypertrophic cartilage and impaired cartilage resorption delaying the formation of 
endochondral bone and resulting in reduced bone growth (Hattori et al., 2010). The 
inhibition of terminal differentiation is a result of Vegfa, Mmp13, RANKL, and 
osteopontin expression. Suppression is a result of SOX9 binding to SRY sites in the 
Vegfa gene (Hattori et al., 2010). Overall, SOX9 acts upon several target genes. 
Enhancers with varying affinities for SOX9 contribute to differential regulation of target 
genes (Mertin et al., 1999).  
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________________________________________________________________________ 
CHAPTER V 
SUMMARY 
________________________________________________________________________ 
5.1 Conclusion  
Following a trans-dimerization DNA-SOX9 model, the hydrophobic platform 
defined by the alpha helices α1 and α2 of the HMG domain provides a favorable binding 
surface for the acceptance of the single alpha helix of the dimerization domain (α0) 
forming a three-helix bundle. Cooperative binding is mediated such that the binding of 
one SOX9 protein to the consensus-binding site facilitates binding to the non-consensus 
site on DNA. In addition, the DNA binding affinity is not affected by mutations to the 
unique di-alanine cluster or two leucines present in the HMG domain. The thermal 
stability of the HMG domain as well as DNA binding is not improved or diminished by 
the presence of a dimerization domain.  Dimerization at tandemly inverted promoters 
with unequal binding sites such as C/C’ utilizes the trans-dimerization recruitment to 
serve as a cogent method of binding. Dimerization is probable once the stronger 
consensus site is bound to a SOX9 protein and can then recruit a second SOX9 to the 
weaker non-consensus site. This differs from two equal binding sites whereby 
dimerization can equally proceed via either site (Peirano and Wegner, 2000). This 
suggests that one dimerization region with another HMG domain on a tandem promoter 
is a fundamental attribute of the binding mechanism. 
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5.2 Future Works 
NMR of SOX9 [101/184] with S9WT would provide visualization of the 
minimal binding of the HMG domain to a single site DNA providing the most 
resolved spectra. This should differ from SOX9 [71/184] with S9WT given the 
affinity for its own dimerization domain to bind to its own HMG domain. If an 
NMR sample becomes hindered by degradation a more suitable alternative 
would be to crystallize the complex under various conditions and determine the 
structure via X-ray diffraction analysis. Crystallization was previously attempted 
with SOX9 [71/164] and CC36 however, the crystal did not diffract. Alternatively, a 
SOX9-SOX5/6 co-complex on a bigger DNA may be more stable for crystallization. 
In addition, to assist with determining the ratio of cis and trans complexes 
within the mixture further cell work would need to be conducted. This 
includes incubation assays to determine the dependency of the type of complex 
formation on temperature and time of incubation. In vitro, this study could be 
affected by incubation time and temperatures such that the on-rate of binding of 
SOX9 almost exclusively as a dimer affecting cooperation and the stability of 
the SOX9-DNA complex can reach a maximum that varies between one minute 
and two hours (Coustry et al., 2010). Fluorescence anisotropy could be used to 
study the dynamics of folding between the unbound, partially bound, and bound states 
given that the fluorophore is bound to a relatively large molecule such as the SOX9 
molecule itself. Concurrently, kinetics and sedimentation studies would reveal 
the reaction mixture (Lippard and Hoeschele, 1979).  
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________________________________________________________________________ 
APPENDIX A:  
A STRUCTURAL MODEL OF THE RNA BINDING SITE IN THE C-
TERMINAL OF THE HUMAN LA PROTEIN 
________________________________________________________________________ 
6.1 ABSTRACT 
The human La protein (hLa) is a RNA-binding protein with diverse roles in viral 
and cellular RNA metabolism. The RNA chaperone activity of hLa assists with the 
folding of RNA into secondary structures. Folding assists in functional structures 
favorable for internal ribosome entry site (IRES)-mediated translation initiation by 
assisting the correct start site usage. The C-terminal of hLa is highly unstructured and 
upon binding to RNA and initiating a conformational change is predicted to form an 
alpha helix in the short basic motif (SBM) of hLa. Transitions in secondary structure are 
studied using nuclear magnetic resonance (NMR) titrations between the unbound protein 
and its bound state to a 12-nucletoide trailer RNA; a small subsection of pre-tRNA that 
hLa is known to bind to. In addition, numerous NMR titrations were conducted to 
determine the extent to which hLa binds to an array of RNAs. 
6.2 THESIS OBJECTIVE & OVERVIEW 
Given the structural similarities between Larp7 and hLa it begs the question 
whether bound RNA can induce a confirmation change and formation of an extended 
third alpha helix in hLa in a similar manner to the complex formed between Larp7 and 
RNA (Figure 26B) (Singh et al., 2013). The array of RNAs includes a 12-nucleotide 
trailer, A20, 5’OH double stranded and single stranded RNA, and triphosphate RNA. The 
12-nucleotide trailer RNA is part of a larger pre-tRNA that hLa is known to bind to.
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More importantly, there could be two essential binding sites in the C-terminal 
constructs of hLa working in a cooperative manner. This includes the initial recognition 
and binding affinity of the RNA recognition motif 2 (RRM2) for RNA as well as the 
presence of the SBM to then lock in and form a final low energy conformational state of 
the RNA-hLa complex. The affinity of the SBM for RNA is only increased once the 
RRM2 has recognized the RNA first. The approach is to use Nuclear Magnetic 
Resonance (NMR) spectroscopy to titrate a stable hLa construct with the 12-nucleotide 
trailer. This is a result of previous circular dichroism data that suggests that complexing 
with this particular RNA yields the lowest energy structure and potentially most stable 
complex. The objective is to determine if the SBM becomes structured and forms an 
extended third alpha helix upon binding to RNA. It is predicted that the RNA binds into a 
groove made between the third alpha helix and the rest of the RRM2. The structure of the 
hLa [225/334] construct has been predetermined by Jacks et al 2003 and the re-
assignments can assist in the determining novel assignment post-C-terminal 334 on the 
CTD of hLa (Jacks et al., 2003; Sanfelice et al., 2004). The constructs for the hLa 
(Figure 27B) in this study begin at amino acid 225 and end at various amino acids 
including 332, 339, 344, 363, 375, and 408 at the C-terminal.  It has been demonstrated in 
preliminary data that the SBM is important for binding.  
6.3 LITERATURE REVIEW: Human La (hLa): A RNA-Binding Protein 
La was first identified as an autoantigen in Sjorgens Syndrome B and Lupus 
Erthymatosus (Kuehnert et al., 2015). Human La (hLa) exhibits numerous roles in viral 
and cellular RNA metabolism (Kuehnert et al., 2015). These processes include stabilizing 
mRNA, mRNA translation via interaction between its RNA-binding surfaces and mRNA, 
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processing of RNA polymerase III transcripts, and micro RNA processing (Dong et al., 
2004; Kuehnert et al., 2015; Teplova et al., 2006). It is a ubiquitous RNA-binding protein 
that has chaperone activity in eukaryotic cells (Phizicky and Hopper, 2010; Wolin 
and Cedervall, 2002). It is an essential protein in mice but can be knocked out in 
yeast. It binds to a variety of RNA transcripts such as pre-tRNAs and RNA 
Polymerase II transcripts (Kotik-Kogan et al., 2008). As a RNA chaperone, La assists 
with non-covalent folding or unfolding of RNA (Herschlag, 1995). hLa binds and 
assists RNA into folding into a functional secondary structure (Kuehnert et al., 2015). 
This is favorable for translation initiation assisting with the correct start site usage as 
well as IRES-mediated translation given that mutants lacking the C-terminal region 
are unable to promote poliovirus IRES-mediated translation (Svitkin et al., 1994). It 
contains an atypical RNA Recognition Motif (RRM) consisting of five beta sheets and 
three alpha helices that directly recognizes RNA (Singh et al., 2013). In addition, the 
highly disordered C-terminal of hLa enables it to assist in the biogenesis of RNA 
precursors (Kucera et al., 2011). In parallel, the C-terminal of hLa becomes 
structurally organized upon binding to RNA as a result of its basic amino acids being 
involved in RNA interactions (Goodier et al., 1997). It prevents newly synthesized RNA 
from forming non-functional structures and prevents exonuclease digestion (Alfano et al., 
2004; Wolin and Cedervall, 2002). It is ATP independent and maintains a high degree 
of disorder even in its lowest energy structural confirmation.  
The study of hLa as an RNA-binding protein is based on the entropy 
transfer model that describes the role of structural disorder in chaperone function 
(Figure 26A). A disordered chaperone binds to a partially mis-folded RNA or protein 
substrate non-specifically (Tompa and Csermely, 2004). The recognition motif anchors 
the chaperone 
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Figure 26: (A) The entropy transfer model describes the role of structural disorder in chaperone function. First, a disordered 
chaperone (orange) binds to a partially mis-folded RNA or protein substrate (blue) nonspecifically. The recognition motif (green) 
anchors the chaperone to the substrate. Secondly, a disordered region of the chaperone projects outward and eventually makes 
contact with the disordered region of the substrate. The chaperone becomes ordered while the substrate unfolds due to entropy 
transfer. The unfolded substrate creates flexibility in itself as a means to find a native or lower energy confirmation by 
maintaining close proximity to the folded chaperone. It is possible that the chaperone has multiple contact and release in rapid 
time points until it finally releases a folded substrate and can resume the entire catalytic processes again. (Adapted from Tompa, 
P., and Csermely, P. (2004). The role of structural disorder in the function of RNA and protein chaperones. Faseb J. 18, 1169–
1175.) (B) Structure of Larp7 RRM2 with an unstructured C-terminal tail prior to the binding of a TER stem 4 RNA to the 
RRM2. Upon binding a confirmation change in the structure of the protein-RNA complex leads to the formation of an alpha 
helix C-terminal to the third alpha helix. (C) The structural similarities between Larp7’s RRM2 and hLA’s RRM2 include the 
four beta sheets and three alpha helices as well as the unstructured C-terminal tail at the end of the third alpha helix. (D) The 
change in structural confirmation of hLA’s RRM2 is a result of RNA binding. The unstructured C-terminal tail becomes an alpha 
helix due to entropy transfer. (Adapted from Singh, M., Choi, C.P., and Feigon, J. (2013). xRRM: a new class of RRM found in 
the telomerase La family protein p65. RNA Biol 10, 353–359.)     
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to the substrate (Naeeni et al., 2012). Secondly, a disordered region of the chaperone 
projects outward and eventually makes contact with the disordered region of the substrate 
(Tompa and Csermely, 2004). The chaperone becomes ordered while the substrate 
unfolds due to entropy transfer (Tompa and Csermely, 2004). The unfolded substrate 
creates flexibility in itself as a means to find a native or lower energy confirmation by 
maintaining close proximity to the folded chaperone (Tompa and Csermely, 2004). It is 
possible that the chaperone has multiple contact and release in rapid time points until it 
finally releases a folded substrate and can resume the entire catalytic processes again 
(Tompa and Csermely, 2004).  
The relationship between p65; a member of the Larp7 family, and hLa are similar 
in their CTD structures but with less conserved sequences in their CTD than NTD 
enabling the structures to differ between the two proteins. In the CTD, they both contain 
five beta sheets and three alpha helices in a βαββαβ'βα fold including the unstructured C-
terminal tail at the end of the third alpha helix (Figure 26C) (Singh et al., 2013). This 
differs from a canonical RRM that consists of four beta sheets and two alpha helices in a 
βαββαβ fold (Singh et al., 2013). An unstructured C-terminal tail in Larp7 forms a 
structured alpha helix C-terminal to the third alpha helix upon binding of a telomerase 
RNA (TER) Stem 4 RNA to the xRRM2 (Singh et al., 2013). The xRRM2 is an atypical 
motif with one extra alpha helix and beta sheet in comparison to the standard RRM 
(Singh et al., 2013). Analysis of p65 revealed a novel-binding site in the xRRM2 of hLa 
that has affinity for RNA. The RRM2 of p65 is atypical with a disordered tail. Upon 
binding to RNA, p65 becomes ordered for a hierarchy of assembly between of telomerase 
RNA (Singh et al., 2012).  
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The crystal structure of p65-C with Stem IV of TER illustrates that when bound to 
RNA, the C-terminal tail is now structured with an alpha helix extension into the third 
alpha helix (α3) (Singh et al., 2012). This extension binds to the major groove of the S4 
of TER opening two C-G base pairs on the either side of G121 and A122 that results in a 
105° bend of the RNA. The GA bulge protrudes out and interacts with residues on the 
RRM (Singh et al., 2012). The high-affinity binding requires both the atypical RRM and 
the C-terminal tail (Singh et al., 2012). This provides insight about the importance of the 
loop prior to the last alpha helix in the C-terminal and if it behaves in a similar manner to 
the shift in p65 (Singh et al., 2013). Sam Sharifi from Dr. Mark Bayfield’s lab 
conducted radioactive electro mobility shift assays demonstrating  that increasing the 
length of the C-terminal of hLa constructs enables shifting to a RNA bound state at 
lower hLa concentrations (i.e. a lower Kd). This suggests that the binding constant will 
decrease as the hLa constructs increase in their C-terminal amino acids. In addition, 
K316A and K317A mutations to the alpha helix demonstrate a loss of function. This 
provides insight into the importance of this final alpha helix to make contact and how 
mutations to this specific region may abolish the structure of the alpha helix.  
The structure of the human La (hLa) protein contains 408 amino acids in 
length and weighs 47 kDa. hLa contains three RNA binding surfaces (Figure 27A) 
including the La motif (LAM),  RNA recognition motifs (RRM) 1 (RRM1) and a non-
canonical RRM2 (Kuehnert et al., 2015). It consists of the N-terminal Domain (NTD) 
containing the LAM and RRM1 making up the La Module. The C-terminal Domain 
(CTD) contains the RRM2, nuclear retention signal (NRE), short basic motif (SBM), 
and nuclear localization signal (NLS) (Horke et al., 2004; Wolin and Cedervall, 2002). 
All three RNA-binding 
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Figure 27: (A) Structure of the human La (hLa) protein. The N-terminal domain (NTD) consists 
of the La module that harbors the La Motif and the RNA Recognition Motif 1 (RRM1). The C-
terminal domain of interest beginning at amino acid 225 consists of RRM2, the Nuclear Retention 
signal (NRE), the Short Basic Motif (SBM), and Nuclear Localization Signal (NLS). In the CTD, 
Serine 366 is a site for phosphorylation. (B) The various CTD constructs of hLa that are tested as 
part of the study, along with their conserved domains. (Courtesy of Sam Sharifi)            
A 
B 
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surfaces of hLa interact with the Hepatitis C virus and is required for the virus to 
translate via an internal ribosome entry site within independent regions (Ali et al., 
2000; Martino et al., 2012; Pudi et al., 2003). However, the RRM1 and RRM2 
cooperate to internally recognize the RNA sequences derived from the Hepatitis 
B virus (Alfano et al., 2004; Horke et al., 2002). In the CTD, Serine 366 (Figure 27A) 
is a site for phosphorylation (Fan et al., 1997; Schwartz et al., 2004). When hLa 
is present in the nucleus it gets phosphorylated by Casein Kinase-2 (CK2), however 
this phosphorylation does not occur in the cytoplasm (Schwartz et al., 2004). In 
hLa, Serine 366 lies in a region with basic amino acids N-terminal to it and acidic 
amino C-terminal to 366 (Kuehnert et al., 2015).  
6.4 EXPERIMENTAL METHODS: Protein Expression and Purification of His6-
hLa [225/332], His6-hLa [225/339], His6-hLa [225/344], His6-hLa [225/363], and His6-
hLa [225/408] for NMR 
E.coli BL21 (DE3) cells expressing all His6-hLa constructs were grown at 37°C 
shaking at 200rpm in 3 Ls of M9 minimal media supplemented with 1 g/L [15N] 
ammonium chloride as a means of being the sole nitrogen source. The media was 
supplemented with 50 µg/mL of Kanamycin in a 2.8 liter Allen flask. Cells were grown 
to an exponential phase reaching an optical density (OD600) of ~0.8-1.0. Cells were 
induced with 1.0mM IPTG (Wisnet Inc) and the temperature was reduced to 16°C at 
200rpm for a 16-18 hour post-induction period for soluble protein production. Following 
the post-induction period, cell pellets were collected by centrifugation at 7000rpm for 15 
minutes at 4°C and placed in the -20°C freezer for a minimum of one hour. Cells were re-
suspended over ice in 25mL of T300 supplemented with 100µL of Thermo Scientific 
Halt™ Protease Inhibitor Cocktail (100X). The re-suspended cells were lysed via three 
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passes of compression at 15000psi using the French Cell Press. The cell lysate was kept 
over ice until centrifugation at 17000rpm for 30 minutes at 4°C using a Beckman 
centrifuge. The soluble extract was then increased to pH 7.0 using Tris-HCl pH 7.5 and 
purified over a 10mL slurry of NI-NTA resin (Qiagen) column primed in T300 
at 2ml/minute. This was followed by a 100mL wash of 2M urea supplemented 
with T300 at 3ml/minute provided that the lysate was added over the beads. The 
column was further washed with 150mL of 10mM and 40mM imidazole supplemented 
with T300 at 3ml/minute. The his-tagged hLa proteins were eluted with 250 mM 
imidazole enriched with T300 at a rate of 2mL/minute following priming the 
column with 250 mM imidazole for approximately 20 seconds. After collecting 
approximately 80mL of elution, 1mM PMSF was added.  
The elution was concentrated down via ultrafiltration using a Sartorius 
5000 MWCO filter to 5mL spinning 5600rpm (Eppendorf Centrifuge 5430 R) at 4°
C. The elution was further purified using the AKTA FPLC gel filtration using a
Sephacryl S100 16/60 column (GE Biosciences) equilibrated with T300 supplemented 
with NP-40 and 0.2% NaN3. Fractions pertaining to the correct molecular weight of the 
protein of interest were then confirmed at the correct molecular weight on a 12% SDS 
gel using a protein ladder (Biorad) and visualized with Fast SeeBand Single Step 
Protein staining solution (FroggaBio) on the Alpha Imager HP system (Alpha 
Innotech). Verified fractions were pooled and concentrated by ultrafiltration using a 
Sartorius 5000 MWCO. The molar concentrations for all SOX9 constructs were 
calculated from the A280 using the extinction coefficient calculated using 
the ExPASy ProtPram tool (http://web.expasy.org/protparam/) using 
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the confirmed amino acid sequence. Pure protein was concentrated to 0.2-0.3M using a 
MWCO 5000 and supplemented with 10% D2O for unbound protein. In addition, a 1:1 
ratio at 0.6 mM of a 12-nucleotide RNA trailer to hLa protein was constructed to 
collect bound HSQC data.  
6.5 RESULTS: Stability of hLa Constructs  
The expressions of hLa [225/332], hLa [225/339], hLa [225/344], 
hLa[225/363], hLa [225/408] were all confirmed with their correct molecular weight at 
13.2kDa, 14kDa, 14.5kDa, 15.4kDa, and 20.6kDa. Expressions of all hLa constructs 
(Figure 28) were more limited in N15 media than LB. All constructs were 
subjected to a profuse amount of degradation and aggregation. However this issue was 
controlled for by culturing a higher quantity of cells, lower post-induction 
temperatures, protease cocktail inhibitors, PMSF, urea washes, and keeping the 
lysates, protein fractions, and samples on ice and frozen during overnight periods at 
-20°C with a minimum of 10% glycerol.
1H-15N-13C HSQC Nuclear Magnetic Resonance (NMR) Spectroscopy of His6-hLa 
[225/332], His6-hLa [225/363], and His6-hLa [225/363]   
HSQC data were collected on a 700 MHz Bruker magnet at a 1:1 
concentration with various RNAs and hLa constructs.  Shifts in peaks from the spectra 
of unbound hLa verses bound RNA-hLa demonstrated the affinity of 
hLa for particular RNAs. When His6-hLa [225/332] was titrated with 
5’OH double-stranded RNA (Figure 29A) there was peak shifting. This was a 
similar case when His6-hLa [225/408] was titrated with 5’OH double-stranded 
RNA (Figure 29B). Likewise, hLa[225/363] peaks shifted when bound 
to 5’OH double-stranded RNA (Figure 30A) as well as poly-A20 RNA (Figure 30B).  
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Figure 28: Confirmation of hLa constructs; hLa [225/332], hLa [225/339], hLa[225/344], hLa[225/363], hLa [225/408] are also 
confirmed at the correct molecular weights at 13.2kDa, 14kDa, 14.5kDa, 15.4kDa, and 20.6kDa. Visualized on a 12% SDS gel using 
a protein ladder (Biorad Precision Plus Protein™ Dual Color Standards) and visualized with Fast SeeBand Single Step Protein 
staining solution (FroggaBio) on the Alpha Imager HP system (Alpha Innotech). Arrows indicate the band with the correct molecular 
weight.  
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Figure 29: 1H-15N HSQC spectrum of hLa constructs unbound and bound with 5’OH RNA. (A) 1H-15N HSQC spectra 
of hLa [225/332] unbound (purple) and bound to 5’OH RNA (green). (B) 1H-15N HSQC spectra of hLa [225/408] unbound 
(red) and bound to 5’OH RNA (blue). The shifts in peaks of both constructs unbound compared to when bound to 5’OH 
RNA are indicative of binding and a conformational change in the structure upon formation of a RNA-hLa complex.       
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Figure 30: 1H-15N HSQC spectrum of hLa [225/363] unbound and bound to RNA. (A) 1H-15N HSQC spectra of hLa [225/363] 
unbound (brown) and bound to single stranded 5’OH (black). (B) 1H-15N HSQC spectra of hLa [225/363] unbound (brown) and 
bound to A20 RNA (black). The shifts in peaks of hLA [225/363] unbound compared to when bound to either RNA are 
indicative of binding and a conformational change in the structure upon the formation of a RNA-hLa complex.       
A
B
N ppm
N ppm
H ppm
H ppm
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HSQC spectra of hLa [225/332] unbound (Figure 31A) and bound to a 12 
nucleotide RNA trailer (Figure 31B) in a 1:1 concentration of RNA to protein were 
reassigned using the original assignments assigned by Jacks et al 2003 (Jacks et al., 
2003). The overlay (Figure 32A) of both the unbound and bound state differed in their 
spectra and significant shifts were present. Based on the calculated difference in the 
HSQC peak shifts via Dr. Logan Donaldson's UNIX Perl Script (Figure 32B) between 
the unbound and bound spectra it is apparent that there is binding between 
the 12-nucleotide trailer RNA and the hLa [225/332] construct. Several shifts 
that occurred after binding included F23, L30, L36, Q45, F51, G54, G58, I60, 
L61, R84, and I105. There was prominent peak broadening post binding of E87, 
I106, Q109, and E111 in one region of the spectra as well as E34, D35, L83, K99, K103 
within another region of the spectra. K103 only became present post-binding. In 
addition, peaks for F51 and V52 disappeared in the complexed spectra.         
6.6 DISCUSSION: Predicted hLa [225/332] Model and Validation  
The disappearance of peaks between the unbound and bound state could 
reflect transient binding consistent with protein dynamics at the milisecond-to-
microsecond time scale. Plotting the largest peak shifts of hLa [225/332] bound to the 
12-nucleotide trailer RNA on the PDB structure of hLa [225/334] demonstrated that there is
an increase in binding toward the end of the C-terminal of the construct (Figure 33A & 
33B). There is an assumption that the strongest shifts (yellow<orange<red) and surface 
exposed amino acids (Figure 33C & 33D) are involved in RNA binding and provides a
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Figure 31: 1H-15N HSQC spectrum of hLa [222/332] (A) unbound (red) (B) bound to a 12 nucleotide RNA trailer (blue). 
The peaks are re-assigned based on Jacks et al (2003) assignments using the software NMR Analysis.  
N ppm
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Figure 32: (A) 1H-15N HSQC spectrum of hLa [222/332] unbound (red) and bound to a 12 nucleotide RNA trailer (blue). The 
shifts in peaks of hLA [225/332] unbound compared to when bound to the 12-nt trailer RNA are indicative of binding and a 
conformational change in the structure from unbound to bound. (B) Plotted difference in the shift coordinates for each 
assigned peak between unbound hLa [225/332] and bound hLa [225/332] with a 12 nucleotide trailer RNA.     
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Figure 33: NMR structure (PDB ID: 1OWX) of hLa [225/334] RRM2 with significant peak 
shifts between unbound hLa [225/332] and bound hLa[225/332] with a 12-nucleotide trailer 
RNA. Significance determined as weak (yellow); 0.015-0.019, medium (orange); 0.02-0.029, and 
strong (red) ≥ 0.03. (A, B) Cartoon figures rotated at two different angles. (C, D) Reveal the 
potential binding groove for RNA to dock into hLa.  
A B 
C D 
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docking site for RNA to bind to hLa and engage in electrostatic interactions. There is 
also significant shifting in loop three similar to the loop three that shifts in p65. This 
provides some insight as to there being an affinity for RNA along the C-terminal and 
the potential for a change in the structural confirmation of a longer hLa C-terminal 
construct. The ability for the RRM2 to recognize RNA may demonstrate 
cooperative binding such that it increases the affinity for the SBM to become engaged 
and clasp over RNA. This could be the mechanism to which the C-terminal of hLa 
changes confirmation from an unstructured tail to an extended structured alpha helix 
upon binding to RNA.  
6.7 CONCLUSION  
hLa demonstrates a high affinity for various RNAs. The affinity between the 
RRM2 for RNA may demonstrate cooperative binding such that it increases the affinity 
for the SBM to become engaged with RNA and endure a change in confirmation from an 
unstructured tail to a structured alpha helix. More importantly, the structural confirmation 
is altered in the presence of RNA and affects its functional state much like the 
commitment of SOX9 when bound to DNA.  
6.8 FUTURE WORKS 
Using the most stable C-terminal hLa construct, a 15N-13C NMR sample will be 
produced and titrated with the 12-nucleotide trailer RNA to compare the bound and 
unbound shifts in order to assign novel peaks to the potentially structured C-terminal 
when bound to RNA and determine if an extension of the third alpha helix is conformed 
post-RNA binding. Testing the effect of phosphorylation of hLa could enhance the 
understanding of hLa-RNA binding. In the event of hLa serine 366 phosphorylation, the 
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acidic region is exposed and could be decreasing the affinity of hLa to bind to RNA. If 
Serine 366 is not phosphorylated, the acidic amino acids are less exposed enabling the 
basic amino acids to bind to RNA.   
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